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Abstract  
The circulation of substandard medicines remains a serious problem in the resource limited 
countries like Sub-Saharan Africa, where most of the drugs available are imported. Medicines 
sold in these markets are frequently found to have ingredients at concentrations that are too high 
or too low. They tend to contain impurities and poor quality ingredients. They are also often 
labeled inadequately. There are a number of reasons for these shortfalls. For example, many 
medicines that are manufactured for export to developing countries are not regulated to the same 
standards as those for domestic use. Most Sub-Saharan countries lack adequate regulations for 
ensuring the safety and efficacy of their medicines. Porous borders between the countries in the 
region facilitate the illicit importation of drugs and drugs piracy. We surveyed a selection of 
drugs available in six of the 15 countries that make up the Economic Community of West 
African States (ECOWAS) to gauge the extent of, and the main reasons for, the circulation of 
substandard drugs in Sub-Saharan Africa. The six countries were Benin, Burkina Faso, Côte 
d´Ivoire, Ghana, Nigeria and Togo. This dissertation describes the survey and its outcomes. It 
also considers what needs to be done on the regulatory front to improve the quality and safety of 
medicines in the region. Free trade and globalization policies have led to an anarchical invasion 
of poor quality medicines into the markets of developing countries. Nigeria has the biggest 
medicines market in the ECOWAS region, where there are very high activities in cross-border 
and parallel trade in pharmaceuticals. 
Medicines in the ECOWAS region can be purchased from pharmacies and other outlets. Drugs 
for sale can be found exposed in bowls or trays along the streets and in market stalls or carried 
on the head by itinerant hawkers ; all these practices are carried out under inappropriate climate 
conditions. In addition, product-packaging standards vary across markets, and prescription 
recommendations and contraindications also may differ. Differences in product packages remove 
the familiar packaging clues that are so important in the visual detection of counterfeits. Price 
differentials create an incentive for drug diversion within and between established channels. 
There is a lack of effective intellectual property protection and due regard is not paid to quality 
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assurance. Retailers may use formal as well as informal channels and some studies have reported 
significant quantities of smuggled drugs in shops including in batches labeled for exclusive 
hospital use. With drugs entering through porous borders, safety warnings and product recalls are 
more difficult to execute. With the exception of Nigeria and Ghana, drug regulation is not a 
national health policy priority in many West Africa countries. Documentation collected during 
our survey of the national medicine agencies from the six ECOWAS countries illustrated that, 
while on paper there are rules governing the pharmaceutical sector, the implementation of said 
rules in practice is weak due to a lack of political will. 
This study is aimed at evaluating the regulatory flaws and some quality parameters of the most 
commonly used essential drugs. The results will be useful to the ongoing drug registration 
harmonization process and especially to the West African Health Organization (WAHO) in 
developing appropriate intervention strategies to ensure that only effective drugs are allowed on 
the ECOWAS market and to promote the public confidence in the quality of the medicinal drugs. 
This will contribute to the implementation of the Essential Drugs Concept as envisaged in the 
WHO guidelines. Also, to further the findings explored in the previous papers on substandard 
and counterfeit medicines, in particular by broadening the scope of our research to include the 
necessity to transcend the linguistic barrier and duplication of effort (WAEMU /ECOWAS) in 
regional harmonization of drug registration and related regulation, processes and laws governing 
medicines marketing. As a result, this will form an important supplement appeal for awareness to 
what has already been explored in previous publications.  
In our survey, internet searches using Google scholar and PubMed formed the first level of our 
inquiry. We used search terms related to medicine sellers in developing countries and to 
substandard medicines. Between January and March 2010, we purchased, without prescriptions, 
68 treatment packs and blisters of antibacterial agents and an antimalarial from various types of 
drug outlets, i.e. pharmacies, market stalls, drug stores and itinerant hawkers on the street and at 
bus stations. All collected medicines would have been prescription-only products in Western 
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markets. The purpose of our purchase was not disclosed to any of the sellers. The drugs were 
then transported in a sealed black nylon bag to the final field testing location in Germany to 
determine the quality assurance range. They were kept under ideal conditions: stored at ambient 
temperature, in low humidity and away from sunlight. 
Primary screening of the samples was conducted using X-ray diffraction at the Institute of 
Pharmacy, University of Bonn. 
Secondary screening of the samples was conducted using near infrared Raman spectrometry 
(from ServanTech in Frankfurt). In the absence of reliable results from X-ray diffraction and 
Raman spectrometry due to restricted facilities and the non-availability of comparator samples 
(in six cases), with which to confirm the spectrum results, we screened the products using the 
Global Pharma Help Fund’s mobile mini-laboratory, GPHF-Minilab. GPHF-Minilab screening 
was based on the related protocol for disintegration, which awards products a “pass” if they 
disintegrate within 30 minutes. 
We also performed High Performance Liquid Chromatography (HPLC) analyses at the Institute 
of Pharmacy and Food Chemistry at the University of Wuerzburg. The assay methods were 
designed to yield additional information such as the content of active ingredient per unit dose, 
the presence of residual starting materials from synthesis and the principle drug decomposition 
products. This was expected to provide additional information on the quality and safety of the 
analyzed drugs. 
We also performed a visual survey (outer packaging and packaging leaflet) of all purchased  
68 packs and blisters. 
Table 1 provides an overview of the results of our analyses. 
 Overall, we found that:  
87 % (59/68) of samples had obvious labeling errors; 
20 % (1/5) of samples failed disintegration tests; 
20% (1/5) of samples failed thin layer chromatography;  
20% (1/5) of samples failed X-ray diffraction; and  
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6% (1/16) of tested samples failed NIR Raman spectrometry. 
HPLC detected labeled active ingredients in all samples; except for one amoxicillin sample (the 
substance to be examined(X3) was not soluble in the mobile phase. Table7). Six of the nine 
doxycycline samples did not comply with the requirements of the European Pharmacopoeia. 
Their contents were found to be above the 95-105% acceptance limit of declared active 
ingredient. The highest deviation found was 162.19%. The variation of content above the limit of 
105% may be due to bad manufacturing methods. Unknown HPLC peaks, especially in the 
doxycycline measurement, may have been caused by the beginning of degradation 
(epimerization, dehydration, inactivation by means of reactions due to used excipients).As a non-
pharmacopoeial method was used for analysis; the results have to be regarded with caution. 
Differences found in the amounts of active ingredients may also be due to bad manufacturing 
habits (inaccurate weighing, capsules filling) or bad storage conditions either by the 
manufacturer, exposition on market stalls, or during transportation. Most of the drugs we 
collected were manufactured in India. 
Our survey revealed that, it is more likely that the drugs we assessed were substandards, as a 
result of bad manufacturing practices by the company exporting the products and the absence of 
well-established drug regulatory bodies in importing countries, rather than as a result of 
fraudulent manufacturing. Though our findings do not exclude counterfeiting, we did not find a 
single sample in which the labeled active substance had been replaced by another ingredient. Our 
conclusion, that the drugs were less likely to be substandard because of counterfeiting, is also 
based on observations in the field and our discussions with local regulators and manufacturers in 
the surveyed countries. Manufacturing deficiencies included incorrect labeling, illegible package 
leaflet and outer packaging with an incomplete address of the manufacturer. Unknown impurities 
were found in some of the products. Storage conditions in the surveyed countries themselves – 
such as open market stalls or hawkers carrying medicines under the sun – may have also played a 
part in facilitating the deterioration of active ingredients. The huge involvement of unqualified 
persons in the procurement and distribution of drugs in the surveyed countries is likely to be 
another major reason for the circulation of substandard medicines. While the sample size in this 
survey is small, it gives an indication about the availability of substandard antibiotics in the 
ECOWAS region. 
Weak regulatory systems in the ECOWAS countries and inefficient border controls call for a 
regional harmonization of drug regulation. Stricter regulatory rules would compel exporters from 
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countries with established drug regulatory systems to make sure that their export to developing 
countries are of the same high quality as those that they register in their own countries. Drug 
regulation would also go some way towards stopping imports of low-quality/counterfeit drugs 
from other little-regulated markets. 
Establishing means to provide a clearer distinction between counterfeits and substandard 
medicines in the ECOWAS countries may help to enhance the general pharmaceutical quality 
management system within the framework of a new regulatory approach; public education; and 
 dialogue and persuasion before litigation and other punitive measures are implemented. Also, 
trying to convert hawkers and illegal traders to other lucrative activities may be an alternative. 
The ECOWAS region needs to establish adequately equipped and resourced laboratories for drug 
analysis and quality control. Such laboratories should be supported by WHO prequalified quality 
laboratories and other inter-country and inter-regional networks. It appears that when suppliers 
are aware that the quality of their products is being subject to continuous monitoring, they make 
sure that they export drugs that are of good quality (Figure 10).In addition, a pharmacovigilance 
plan needs to be developed in the ECOWAS region as part of the overall medicines regulatory 
system. Boosting regulatory enforcement in the ECOWAS region would be beneficial in terms 
of improving the packaging, labeling and the chemical quality of medicines. Efforts to develop a 
harmonised regulatory framework in the ECOWAS region have already been undertaken. In the 
context of the African Medicine Regulatory Harmonization Initiative, ECOWAS is planning to 
establish a regional co-ordinating medicines registration harmonisation board called the 
ECOWAS Medicines Regulatory Agency (EMRA). It is expected that EMRA would provide 
technical assistance to member state national medicines regulatory authorities and register 
critical products for public health interventions within the ECOWAS region. 
New provisions to control manufacturers, wholesalers and importers should be established. 
Attacking the problem through multiple routes will be the most effective way to combat the 
problems of substandard and illicit marketing of drugs. 
The attainment of quality assurance for medicines in the ECOWAS region should be accelerated. 
The WHO prequalification program, health institutions and donators should emulate the West 
Africa Health Organization (WAHO) in supporting local human capacity building in medicines 
regulatory issues and local pharmaceutical manufacturers through technical and financial 
assistance. The ultimate aim is to help promoting the import of only high quality medicines and 
the domestic manufacture of drugs according to the principles of good manufacturing practice. 
We hope that our survey will increase awareness of the circulation of poor quality medicines in 
           ABSTRACT 
6 
Sub-Saharan Africa and encourage regional harmonization of drug regulation in particular in the 
ECOWAS region.  
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PART 1: INTRODUCTION 
Pharmaceutical markets are distinguished by a number of key features (Scherer 2000)
1
. First, 
drugs are divided into prescription-only and over-the-counter products, with many restrictions on 
the availability of the former. Secondly the demand for pharmaceuticals is generally inelastic, 
reflecting the predominance of a high willingness to pay for medicines. Thirdly, research and 
development costs are relatively high and lastly, patent protection plays a very important role in 
profitability. A frequently observed phenomenon is the "generic competition paradox" which 
occurs when, following the expiry of a patent, generic alternatives enter the market, but the 
originally patented brand continues to be sold at a higher price (Scherer 2000)
2.
Medicine markets 
in developing countries are mostly generic markets. The main difference between the life cycles 
of originator and generic medicines is found in the development phase. While for originator 
medicines the focus is on safety and efficacy data (proven in preclinical and clinical trials), 
generic medicines are assumed to be safe and efficacious if they can demonstrate 
pharmacokinetic parameters similar to the originator product. For generic medicines the focus 
essentially lies on quality aspects. 
Markets play an extremely important role in the distribution of pharmaceutical products in 
developing countries. There is some overlap with other terms frequently used, such as parallel 
markets which arise to evade price, quality and quantity controls in one hand, and black markets, 
which refer to illegal trade (Jones, Lindauer and Roemer 1991)
3
. By contrast, in developing 
countries the sector remains dominated by small-scale retailers, and there are many ambulatory 
sellers, and periodic markets. Pharmacists and pharmacies are relatively rare. (Table12)  
                                                 
 
1
 Scherer, F.M. 2000. "The Pharmaceutical Industry." in Handbook of Health Economics, Volume I, edited 
by A.J. Culyer and J.P. Newhouse: Elsevier Science B.V; available from http://www.kemri 
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Generic pharmaceuticals represent almost two-thirds of total sales in developing countries and 
branded generics are much more important than unbranded generics in sales, their manufacturing 
is predominantly for the home market. Cultural and behavioural patterns also have a key bearing 
on the consumption of medicines. Although pharmacies are scarce in most rural and some 
suburban areas, they represent the main source of non-prescription medicines for most people, 
provided the shelves are well-stocked. As a result, a great deal of self-diagnosis, self-medication 
and re-use of prescriptions occurs. This gap is often maintained or even gets wider over time. 
There are essentially two markets or market segments: one of price insensitive consumers, 
willing to pay high prices for the original brand, and another consisting of price sensitive 
consumers willing to shift to generics (Suh et al. 2000)
4
. Price insensitivity in the first group may 
arise because established products have built up accumulated goodwill and reputation during the 
patent period. Higher prices may also be maintained because consumers lack information about 
generics, because they are concerned about the quality of newer products, or because prescribers 
and patients are not directly affected by the financial consequences of their drug choice 
(Ferrandiz 1999)
5
. In developing countries, spending on medicines comes largely from 
household resources (table 12) and prescribed medicines have to be paid out of pocket at the 
time the person is ill. Price differentials create an incentive for drug diversion within and 
between established channels; there is a lack of effective intellectual property protection; and due 
regard is not paid to quality assurance. Parallel trade in pharmaceuticals generates a number of 
monitoring difficulties which may pose significant threats to public safety. With drugs entering 
through porous borders, safety warnings and product recalls are difficult to execute. In addition, 
product-packaging standards vary across markets, and prescription recommendations and 
contradictions also may differ. Differences in product packages remove the familiar packaging 
clues that are important in the visual detection of counterfeits. 
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Parallel trade results in unregulated distribution pipelines and weakened regulatory control of the 
supply chain, both of which are characteristics that facilitate counterfeiting and substandard 
drugs. Although practically all types of pharmaceutical products have been shown to be 
involved, the existing data suggest that anti-infectious agents, particularly antibiotics and 
antiparasitic agents are the most counterfeited products in developing countries
6
. 
The essential medicines list, first assembled by a World Health Organization (WHO) expert 
panel in 1977 and revised every two years to reflect current health challenges, is an inventory of 
medicines which address pressing local/regional health needs. Medicines are identified through 
an evidence-based process and quality, safety, efficacy and cost-effectiveness are key selection 
criteria. In close cooperation with national regulatory agencies and partner organizations, the 
Prequalification Programme aims to make quality priority medicines available for the benefit of 
those in need at affordable price. This is achieved through evaluation and inspection activities, 
and by building a national capacity for sustainable manufacturing and monitoring of quality 
medicines. Literature related to pharmaceutical products in developing countries predominantly 
addresses concerns about the lack of effective drugs and their high cost, through discussion of 
the role of essential drugs policies, patent law, and incentives for research and development for 
neglected diseases
7
. Few studies have examined drug quality
8
,
9
 and have investigated poor 
quality drugs in terms of the correct amount of active ingredient. This paper focuses on quality 
assurance in procurement and distribution channel. 
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PART 2:  BACKGROUND INFORMATION AND LITERATURE REVIEW 
CHAPTER I:  Regulatory Aspects of Medicines in Sub-Saharan Africa 
This chapter gives an insight of the problems of quality assurance globally and within the 
surveyed ECOWAS region as well as the preliminary Literature Review. The rationale of the 
study is discussed along with problem analysis and recommendations. It brings the reasons and 
importance of the study (pooling technical and human resources through regional harmonization) 
into focus. 
1.1. Functions in the Regulation of Medicines  
The administrative elements of drug regulation carry out the regulatory functions which include 
licensing of premises, human resources and practice, inspection of manufacturers and 
distributors, product registration and assessment, enforcement, quality control of drugs and 
public awareness. The relevant legislation will specify the requisite qualifications (and 
sometimes also the number) of personnel handling specific tasks, the procedures used to 
produce, import and distribute pharmaceutical products and the health and safety conditions of 
the premises in which any of these processes take place. The manufacturing, importation and 
distribution premises are inspected to ensure compliance with regulatory specifications. The 
technical elements form the major requirements to be followed. Every activity in the regulatory 
functions is expected to be carried out efficiently on all levels within a country. Guidelines set 
out the conditions, content, format of applications, and the detailed technical requirements 
against which dossiers will be assessed based on international guidelines. The framework allows 
for a comparison of drug regulation between countries. Drug regulation can spill over from one 
country to another; the drug policy in one country can affect another as the knowledge of what 
happened in one country can help another prepare for similar challenges in future. To provide 
credible regulatory services, National Medicines Regulatory Authorities (NMRAs) must have 
specific measures in place to avoid conflict of interest in decision-making, to make their rules 
and decisions transparent. Regulation is traditionally seen as the use of bureaucratic and 
administrative controls by governments to correct market failures. Without adequate policy, 
human resources, finances and infrastructure, drug regulation will fail. The framework below 
(Figure 1) reflects the building blocks comprising the regulation of medicines. The level of 
regulation indicates the level at which the various regulatory functions are undertaken. The 
political structures of a country determine the overall governance of drug regulation. Medicines 
regulation is a public policy that restricts private sector activities in order to attain social goals. 
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Source: Ratanawijitrasin S. Wondemagegnehu E, (2002) Effective drug regulation- A multicounty study. A book 
published by WHO Library Cataloguing-in-Publication Data ISBN 92 4 156206 4.Document accessed  in Cotonou 
Benin on September 22, 2011.  
Every regulatory function contributes to ensuring the safety quality and efficacy of drugs. The 
action taken by the authority should cover all drug regulatory functions in a balanced fashion. 
The regulatory process should be systematically monitored in order to identify problems and 
determine whether actual activities match the intended actions. Governments are responsible for 
carrying out regulatory functions to ensure that all drugs on the market are of acceptable quality, 
safety and efficacy. A most basic question is whether drug regulation achieves its declared aim, 
which is protection of the public from ineffective, unsafe, or inadequately tested drugs. 
Moreover, the drug regulatory agencies should become a learning organization which routinely 
conducts self-assessment and continuous quality improvement. Peer review by drug regulatory 
authorities in other countries can serve as a mean of external auditing, whereby the performance 
of one agency can be compared with that of its peers. Drug Regulatory Authorities (DRA) 
should communicate regularly with their client. We emphasize that no guidance can cover all 
eventualities, and common sense and a clear focus on the needs of the regulatory authority are 
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the best guides.  Educating citizens about the efficacy, safety, quality and rational use of drugs 
will ultimately enhance the achievement of regulatory objectives. 
1.2. Quality Assurance of Pharmaceutical Products 
Quality assurance of pharmaceuticals is a major public health challenge, particularly in the light 
of growing cross-border health issues and the international dimension of trade. In many 
developing countries, an unfortunate combination of two factors exists. On the one hand, there is 
predominance of imported finished products and on the other, a lack of adequate analytical 
services and appropriate human resources. The movement of pharmaceutical products in 
international commerce necessitates various safeguards on the part of importing countries and 
institutions to assure that pharmaceutical products are safe, effective, and of adequate quality 
when received by their final consumers. Quality assurance of pharmaceutical products is based 
on a reliable system of evaluation and registration to establish safety, efficacy, and confirmation 
through inspection that the manufacturing conditions fulfill requirements for Good 
Manufacturing Practices. Quality assurance of an imported product would ideally include: 
i) Registration of the product in the country of manufacture; 
ii) Approval of manufacturing conditions by pharmaceutical inspection of the manufacturing 
plant; 
iii) Licensing of the product in the country of importation 
iv) Pharmaceutical quality analysis of a batch of the product by the manufacturer's laboratory 
before the product is released; 
v) Additional analytical testing should be done to confirm that the batch received did not 
deteriorate during transit. 
Such an ideal set is practically rare in developing countries where technical tools and financial 
resources to set-up national quality assurance systems are not easily available. Due to political, 
social and cultural affiliations, markets show substantial regional differences in availability and 
promotion of drugs. This variation depends on affluence, health requirements, capacity for the 
local manufacturing, and the restrictions which countries may impose, to control any dangerous 
or inappropriate use of drugs. Because of the limited number of industrial plants, the majority of 
developing countries import most of their drugs, and transnational corporations are adept at 
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exploiting variations in such markets. Commercial interests may conflict with public health 
needs in developing countries, particularly when people are poisoned
10,11
due to inadequate 
restriction of pharmaceutical use, misleading advertising or inappropriate labeling.All finished 
drug products should be identified by labeling, as required by the national legislation, bearing at 
least the following information: 
 the name of the pharmaceutical product; 
 a list of the active ingredients (if applicable, with the International Non-proprietary 
Names (INNs)), showing the amount of each present,  e.g. number of dosage units, mass 
or volume; 
 the batch number assigned by the manufacturer; 
 the expiry date in an un-coded form; the directions for use, and any warnings and 
precautions that may be necessary; 
 the name and address of the manufacturer and the responsible for procurement and 
distribution. 
Quality assurance of medicine plays a major role in ensuring that medicines intended for human 
use meet the minimum requirements or specifications. The National Drug Regulatory Authority 
(NDRA) in a country where a drug is produced is responsible for evaluating and registering the 
drug, inspecting and licensing manufacturing premises. The NDRA is also responsible for 
controlling import and export agents, distributors, wholesalers and retailers; and overseeing 
quality control. Quality assurance is of crucial importance for the success of treatment programs; 
medicines manufactured below established standards of quality can lead to therapeutic failure, 
development of drug resistance and toxic or adverse reactions. The pharmaceutical substance, 
formulation and dosing of any drug for human use are typically described in a monograph 
                                                 
 
10
Singh J et al. Diethylene glycol poisoning in Gurgaon, India, 1998.Bulletin of the World Health 
Organization, 2001, 79(2):88-95.Ref No.99-0329;  available from 
www.who.int/bulletin/archives/79(2)88.pdf.Internet accessed on September 12th, 2011. 
11
Fake meningitis vaccine in Niger (editorial).Scrip, 23 August 1996, 2157:12; available from 
http://apps.who.int/medicinedocs/en/d/Js2300e/16.3.Internet accessed on September 13, 2011. 
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published in the internationally accepted Pharmacopoeia. These monographs provide the 
specifications and standards against which independent quality control testing can be verified, 
and will be important in the quality assurance process. 
1.3. Safety issues of Medicines 
Medicines cure infectious diseases, prevent complications from chronic diseases, and alleviate 
pain. With higher sales rates occurring through non-regulated outlets, the retailers of medicines 
in less resourced countries are an important source of disease treatment. Retailers increase the 
accessibility, the range and reliability of drug stocks, but several marketing failures were evident. 
There is a high occurrence of parallel distribution, information on treatment quality is poor, and 
negative externalities arise from inappropriate drug use. These failures contribute to the use of 
ineffective medicines, under-dosing, and inequitable access to quality care. While some patients 
use just one treatment source, referring to multiple providers is common, and patients may 
combine modern and traditional remedies during one illness- episode. Another widespread issue 
is poly-pharmacy, where providers prescribe unnecessary drugs. For example, rates of antibiotic 
use during fever episodes often vary with unclear justification. 
Drug legislation assigns two types of responsibility to drug regulatory authorities: the authority 
to assess pharmaceutical products thus determine whether they should be registered, and the 
authority to monitor and change the information and registration status of a drug after marketing 
approval through  the pharmacovigilance or post market surveillance. However, the regulation is 
more oriented to pre-marketing assessment than to post-marketing review. Registered products 
are rarely reevaluated. Yet even if pre-marketing assessment has been thoroughly conducted, it 
may not be sufficient to guarantee the efficacy and especially, the quality of a drug throughout its 
entire lifecycle. Emphasis should be placed on post-marketing surveillance. Parallel trade in 
pharmaceuticals generates a number of monitoring difficulties that are not readily apparent but 
pose significant threats to safety and quality. With drugs entering through various channels 
safety warnings and product recalls are difficult to execute. 
Where the pharmacovigilance system is weak or non-existent; a high degree of responsibility is 
placed on medical staff to guard against adverse effects. Such informal surveillance is often 
compromised by the acute lack of healthcare staff in most developing countries, where 
medicines are often prescribed to patients by health auxiliaries who only receive a very short and 
basic training that does not emphasize the detection of drug side effects. Moreover, many toxic 
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side effects are difficult to detect by clinical observation. For example, the rise in temperature 
often observed after post-surgery administration of intravenous fluids is usually interpreted to 
reflect a general degradation of the patient’s condition, but we have noted  instances where this is 
in fact the result of a poor manufacture of the intravenous fluid resulting in contamination with 
pyrogens. In addition patients often have to travel long distances to receive medication and can 
rarely afford the time or financial cost of remaining under hospital supervision. Because 
individual treatments are frequently ineffective, multiple treatments sought during the course of 
an illness episode sometimes result in cumulative over-dosing. 
 Governments’ failures were also evident in the form of a poor quality in public health sector 
treatment, and the absence of an efficient enforcement of regulatory laws. Sesay
12
investigated 
the use of expired essential drugs including Chloroquine (CQ) in Sierra Leone, and the attitudes 
of medical practitioners to the subject matter. The author reports that there were variations in the 
shelf life of CQ products audited, ranging from 3 to 5 years. More worrying, 67% of 
practitioners estimated that expired products could be used despite their diminished efficacy; 
27% of health practitioners in this study stated categorically that expired products should not be 
used. 
Rather than being passive recipients of care and advice, consumers take an active role in the 
choice of outlets, and in some cases, choice of treatment. Treatment seeking takes place within a 
pluralistic health system, encompassing health facilities in the public, non-governmental 
organization (NGO), community health workers, traditional healers and retailers (Williams and 
Jones 2004)
13
 .Many studies found that people very often tend to begin with home treatment, and 
then proceed to the national health center when home treatment strategies were perceived to have 
failed
14
although home treatment remains an important option at all stages of illness. Drug shop 
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 Sesay MM. Expiry dates on pharmaceuticals-some worrying realities in Sierra Leone. International 
Pharmacy Journal.1994; 8:202–206; available from www.ncbi.nlm.nih.gov/pmc/articles/PMC2653781. 
Internet accessed on April16th, 2010 
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Williams, H. A., and C. O. Jones. 2004. "A critical review of behavioral issues related to malaria control 
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visits can be distinguished in a sub-set of household surveys, which show that buying drugs from 
retailers is generally very common. The median percentage of using drug shops during acute 
childhood illness is roughly 50%, although results range from 15% to 82% across various 
studies
15
. In Togo for example, only 20% of children less than 5 years of age with fever were 
conducted to a health center during their illness, while 83% were treated at home with an 
antimalarial, obtained from a street or market vendor
16
. A study in Kenya found that most 
mothers purchased drugs from retail outlets within one day of noticing the symptoms of 
childhood malaria, but the average time lag before a public health facility is reached, was 3 
days
17
although prompt appropriate treatment is rare. However, since some studies have shown 
that early treatment of childhood fever with ineffective drugs may results in severe outcomes
18
, it 
is important to emphasize that in the case of persisting fever, caregivers should seek regulated 
health services in time for proper diagnosis and management. There is some evidence that home 
treatment reduces the time to obtaining care
19
. On the other hand home treatment may lead to 
incorrect diagnosis, and administration of inappropriate dosages in the case of persisting disease. 
Another consequence is a possible delay in seeking appropriate diagnosis and treatment.  
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 This may have severe implications for diseases like Plasmodium falciparum malaria in which 
late diagnosis and therapy can lead to cerebral forms of the disease and high fatality rates. 
The WHO defines appropriate treatment of childhood fever as receipt of an antimalarial within 
24 hours of symptom onset (WHO & UNICEF 2003).It is increasingly recognized that in order 
to improve the majority of treatments for many common health problems, governments have to 
look beyond the public sector and, acknowledge the reality of the widespread retail sector use, 
and address the ways in which policy intentionally and unintentionally influences private sector 
behavior (WHO 1998). The retail sector has been largely ignored, with initiatives generally 
limited to poorly implemented regulation. Problems relating to drug safety (and efficacy) are 
generally due to the use of drugs containing toxic substances or impurities, drugs whose claims 
have not been verified or which have unknown severe adverse reactions, substandard 
preparations or counterfeits. All of these problems can be tackled effectively only by establishing 
an effective drug regulatory system. Guaranteeing the safety, efficacy and quality of drugs 
available to the public is the main goal of drug regulation, and encompasses a variety of 
functions. Key functions include licensing of premises, persons and practices; inspection of 
manufacturing facilities and distribution channels; product assessment and registration 
(marketing authorization); Adverse Drug Reaction (ADR) monitoring; Quality Control (QC); 
control of drug promotion and advertising. Each of these functions targets a different aspect of 
pharmaceutical activities, but all of them must be undertaken simultaneously to ensure effective 
consumer protection. Moreover, no studies have used a regulatory framework to analyze the 
retail market for health care in West Africa (ECOWAS), although such a framework is likely to 
be well-suited to improving quality assurance and address safety issue. This paper is intended to 
address this gap in knowledge. 
 BACKGOUND INFORMATION AND LITERATURE REVIEW 
18 
CHAPTER II: Overview of the Pharmaceutical Environment 
2.1. Pharmaceutical Sector Environment in Surveyed Countries 
Developing countries are mainly located in three continents namely: Africa, Asia, and South-
America. The pharmaceutical challenges show similar patterns across all of these countries. A 
survey of all those regions is unrealistic and even surveying a single continent lies outside the 
scope of this thesis. Sub-Saharan Africa  alone is  a huge batch; due to the allocated time and 
financial limitations, it has been possible to  survey six countries from the economic community 
of West Africa states (ECOWAS) namely Benin, Burkina Faso, Cote d´Ivoire, Ghana, Nigeria 
and Togo. The political reality in these countries significantly influences policies, practices, 
business activities as well as pharmaceutical sector.The major problem encountered in this study 
was the initial reluctance of regulatory bodies to divulge vital information thus revealing their 
level of performance. 
 Economic Community of Western African States (ECOWAS)  
 
Source: http://mapsof.net/map/map-of-ecowas; Internet accessed on December 2011 
The Economic Community of West African States (ECOWAS) was established in May 1975 by 
the treaty of Lagos. The region covers a total area of 5,079,400 km² with a population of about 
268 million. Half of the ECOWAS´ population is located in Nigeria and its economy dominates 
the region. ECOWAS has a need for quick access of quality essential medicines due to its 
disease burden. In general, the region suffers under the burden of Malaria, Tuberculosis, 
neglected tropical diseases and other newly emerging diseases (diabetes and cardiovascular 
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disorder). In addition to these communicable and non-communicable diseases, poverty and 
malnutrition have also an impact on the types of medicines required.ECOWAS is a regional 
institution grouping fifteen countries (including the eight WAEMU [West Africa Economic and 
Monetary Union] member countries): Benin, Burkina Faso, Cape Verde, Côte d’Ivoire, Gambia, 
Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone and Togo. 
Each member of the Economic Community of West African States (ECOWAS) is a multisource 
(generics) importer of pharmaceuticals. The climate in all member countries corresponds to 
Class IV tropical climate according to the International Conference on Harmonization (ICH) 
classification (Grimm, 1998)20.Until early 1980´s the pharmaceutical sector in most ECOWAS 
member countries was monopolized by national agencies. The procurement, handling and 
distribution of medicines were under the control of national pharmaceutical distribution agencies 
which generally were supplied by the previous colonial metropolis and the traceability was 
simple. The scale of poor quality medicines was very low and limited to rural areas where 
national healthcare service was not available. During 1980´s the quasi total countries of West 
Africa had to introduce structural adjustment programs and reforms recommended by the 
International Monetary Fund (IMF). In the health sector, one of the results of implementing the 
reforms was increased participation of the private sector in the importation of pharmaceuticals, 
without a parallel increase in the capacity of technical means and human resources to institute 
effective quality assurance measures. For more than 50 years of existence, countries like Cape 
Verde, Guinea, Gambia Sierra Leone, and Togo have no efficient quality control laboratory
*
. 
During my survey in the Economic Community of West Africa (ECOWAS) countries, I 
witnessed how decadence pharmacy profession is in term of regulation; many people prefer 
purchasing medicines in the market than pharmacies, so that they can get affordable prices. For 
instance, in visited five drug stores only one (20% of vendors at drug stores) in Ouagadougou 
knew the correct dose of Sulfadoxin in Artemisin; this reveals that employees in some official 
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Pharm. 24: 313-325. Drug Development and Industrial Pharmacy (1998) Volume: 24, Issue: 4, Pages: 
313-325 PubMed: 9876591;Abstract;available from www.ncbi.nlm.nih.gov; Internet  accessed on January 
24
th
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Personal Information from WAHO Training on GMP-Inspection for National Medicine Regulatory 
Authorities and local Pharmaceutical Manufacturers in ECOWAS region in PRAIA -Cape Verde March 
2011. 
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pharmacies have no basic pharmaceutical education.  Medicines can be purchased in general 
stores, kiosks, market stalls, formal pharmacies and also from itinerant hawkers. The survey 
countries (Benin, Burkina Faso, Cote d'Ivoire, Ghana, Nigeria and Togo) face considerable 
challenges in ensuring that available medicines are safe, of acceptable quality and efficacious. 
Most of the illicit sellers ignore that under the local climate conditions their medicines are 
readily degraded, some rely exclusively on the expiration date printed on blisters to ensure the 
quality to the consumer. Like most resource-limited countries, ECOWAS (Economic 
Community of West Africa States) depends largely on importation to response to medical needs 
of their populations. Drug registration is a pre-requisite for purchase in resource-limited 
countries, but authorization to register a medicine is often granted on the basis of a simple review 
of documents. Quality is impossible to assure in the absence of proper controls that at minimum, 
include verification of information submitted for evaluation through site inspections, review of 
batch documentation, and random analysis of drugs supplied (European Commission 
Humanitarian Aid Department2006)
21
. Drugs manufactured for export are often not regulated to 
the same standard as those manufactured for domestic use in exporting countries. The purchasing 
power for pharmaceuticals in these countries is very low, most importers and distributors of 
pharmaceuticals tend to pay more attention to low prices rather than to the quality. They source 
their imports from the cheapest suppliers. Suppliers of pharmaceuticals to a market characterized 
by such a low purchasing power as in Benin, Burkina Faso, Cote d´Ivoire, and Togo rely on 
cheap brands, as low prices are favorable to the general population. With such a large difference 
in prices one would be interested to know if those brands are pharmaceutically equivalent. In 
addition, the free substitution of one brand to another is practiced on the assumption that those 
dosage forms which contain the same amount of active ingredient are equivalent. It is a known 
fact that the bioavailability of generic identical drugs might shift
22
. The outcome of such 
variations may have serious therapeutic implications, especially for drugs with a narrow 
therapeutic index (aminoglycoside antibiotics) and a steep dose response curve. It is reasonable 
to discourage substitution between different brands/generics, unless the necessary measures have 
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been taken to show that the products are equally effective in delivering the medicament to the 
systemic circulation. 
In an environment of multi-source importation, market preference for cheaper brands and lack of 
quality control facilities, the trade in substandard / counterfeit drugs is likely to flourish, rending 
the quality assurance of drugs on market a challenging problem. Moreover, the confidence of 
health workers and patients in the health system is easily eroded when there are reports (even 
when they are unsubstantiated) of substandard drugs in circulation. Prescribers overwhelmed by 
the multitude of brands, (some of which are perceived to be of poor quality) may prefer the use 
of expensive brands as they associate good quality with high price. This may negatively 
influence the achievements made through the efforts by the governments to increase access to 
safe, effective and affordable medicinal products to the majority of their citizens. 
Since its foundation in 1975, the West African economic organization has no harmonized 
information available on the quality of drugs marketed in ECOWAS region and there is neither a 
WHO-prequalified quality control laboratory nor a prequalified local manufacturing plant in the 
region.  It is therefore important to encourage local pharmaceutical manufacturers to upgrade 
their facilities as well as to improve on human resource capacity and technology to increase the 
production of quality medicines. This will contribute to the implementation of international 
accepted Quality standard in manufacturing (Good Manufacturing Practice) and distribution 
(GDP: Good Distribution Practice). Coincidentally, the linguistic differences are also reflected in 
the systems of procurement and distribution of medicines, production, marketing, and contribute 
to the challenges facing medicines registration and the harmonization of regulations as a public 
health tool for improving accessibility, affordability and availability of safe, efficacious and 
quality medicines in the region.The West Africa Health Organization (WAHO) was formed in 
1987 by a protocol, which grants the WAHO official status as a specialised agency of all the 
 15 ECOWAS countries.The driving force behind the WAHO's creation was the incongruence of 
the agendas that were being pursued by the two inter-governmental health organizations that 
existed in the region at the time. These were the Francophone “Organisation de Coordination et 
de Cooperation pour la Lutte Contre les Grandes Endemies” (OCCGE) and the Anglophone 
West African Health Community (WAHC). It was felt that, as matters of health are not bound by 
linguistic differences, it would benefit the people of the region to synchronize the activities of 
the two organizations and combine resources to enhance the impact of their programs in West 
Africa. The OCCGE and WAHC therefore merged to form the WAHO, an organisation 
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committed to transcending linguistic barriers in the region to serve all the 15 ECOWAS Member 
States. Since then, communication and information exchange between member countries have 
improved tremendously and has made integration easier and more beneficial to all Member 
States. Currently a consensual draft of ECOWAS harmonized regulation on quality of drugs 
marketed in West Africa is delayed by the hesitation from the French speaking countries´ group 
(UEMOA: Union Economique et Monetaire Ouest Africaine). To my view, this hesitation seems 
to be a manipulation from foreign pharmaceutical partners. This study is aimed at evaluating 
some quality parameters of the most commonly used essential drugs. The results will be useful to 
the ongoing harmonization process and especially to the West African Health Organization 
(WAHO) in developing appropriate intervention strategies to ensure that only effective drugs are 
allowed on the ECOWAS market and to promote the public confidence in the quality of the 
medicinal drugs. This will contribute towards the implementation of the Essential Drugs Concept 
as envisaged in the WHO Prequalification Program. This study is significant because the 
people’s right to health includes the right to access a reliable standard of healthcare and 
assurance that drugs received are not only genuine but safe, effective, and affordable.  
 
2.2. Analysis of the Drug Situation in Nigeria 
With a population of around 167 million Nigeria represents a large market for drugs. Whatever 
happens in Nigerian pharmaceutical market has an impact on medicinal products circulating in 
the ECOWAS markets. ”Theoretically the Nigerian industry has a capacity to cover between 50 
– 75% of the nation’s drug needs. However, the actual production lies below 30% thus 70% of 
all drugs on the Nigerian market are imported.” (Okoli, 2000)23. In Nigeria, the National Agency 
for Food and Drug Administration and Control (NAFDAC) has enlarged the scope of counterfeit 
drugs to include drugs without the full name and address of manufacturers, drugs labeled “For 
Export Only”, expired and relabeled drugs with the intention of extending their shelf lives, drugs 
containing banned substances and drugs not registered by NAFDAC. NAFDAC focuses too 
much on registration and not enough emphasis on regulating the distribution system. Fake drugs 
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were first noticed in Nigeria in 1968, as the situation deteriorated, Nigeria was rated as the 
country with the highest incidence of fake drugs in 2001. A study in 2001 that assessed the 
content of drugs from pharmacies in Nigeria revealed that around half of the preparations had 
concentrations outside the upper and lower limits of the pharmacopoeia applicable in the region 
from which they originated. Consequently, made-in-Nigeria drugs were banned in other West 
African countries. The issue of fake drugs and others is assuming new dimension as to who is 
responsible or not for averting the situation.  NAFDAC has appointed analysts in India – which 
is a major exporter of medicines to Nigeria – who now certify drugs before they leave India for 
Nigeria. For imported products from all countries, the Nigerian medicine agency now requires 
mandatory pre-shipment information to be provided by importers. The Agency (NAFDAC) also 
held a summit with Indian authorities, in order to sensitize and convince them to help Nigeria by 
stopping exportation of substandard drugs to the country. It held another one in conjunction with 
House committee on Health with ambassadors of the countries identified as the root of the influx 
of fake drugs to the country like India, Indonesia, China, Pakistan, and Egypt; a position was 
reached that they will help Nigeria in addressing the issue. 
2.2.1. Pharmaceutical Regulation 
Amongst the regulatory bodies are: (i) The National Agency for Food and Drug Administration  
and Control (NAFDAC), (ii) The Pharmacists Council of Nigeria and (iii) Federal Task Force on 
Counterfeit and Fake drugs, these are the three bodies relevant to the study. NAFDAC was 
established by decree 99 of 1993, this decree regulates and controls the production, importation, 
exportation, advertisement, use and sale of all drugs, processed food, cosmetics, medical 
services, including all drinks, chemicals and so on. NAFDAC is established to:  
 conduct appropriate tests and ensure compliance with standard specifications 
designated and approved by the council for the effective control of quality of food, 
drugs, cosmetics, medical devices, and their raw material as well as their production 
processes in factories and other establishments;  
 undertake appropriate investigation into the production premises and raw materials 
for food, drugs, cosmetics, medical devices,  and establish relevant quality assurance 
systems, including certification of the production sites and of the regulated products;  
 undertake inspection of imported food, drugs, cosmetics, medical devices, and 
establish relevant quality assurance systems and of the regulated products; 
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 grant authorization for the import and export of narcotic drugs and psychotropic 
substances as well as other controlled substances;  
 collaborate with the National Law Enforcement Agency in measures to eradicate drug 
abuse in Nigeria. 
Recently, official signing of NAFDAC green page was done to ensure only registered and 
reliable drugs were allowed to be used in hospitals, pharmacies and others health establishments. 
With NAFDAC green pages all stakeholders in the industry obtained a legitimate common 
ground, where their products and services would be show-cased to Nigeria and the world, 
through three media; the book form which will be in volumes and yearly, compact disks and via 
an established internet homepage. NAFDAC has improved screening of drugs in the field; it has 
undertaken forensic analysis of low quality drugs and pursued those selling and marketing them. 
Screening has improved with the deployment of several small portable laboratories, known as 
Global Pharma Health Fund e.V. Minilabs® for rapid product screening where formal laboratory 
facilities are sparse. NAFDAC is also conducting a survey and audit of all drugs on sale in order 
to build a pharmaceutical database. From 2002, drug failures fell to roughly 16% in 2006 and are 
now down to about 10%*. NAFDAC is pushing further by being the first anti-counterfeit 
department in the ECOWAS region to deploy six hand-held laser (Raman) spectrometers, which 
can provide immediate authentication of drugs. This deployment is helping to close down more 
of those locations still selling fake products. Despite the achievement, NAFDAC has no power to 
prosecute all offenders connected with faking or manufacturing of substandard drugs, anybody 
arrested with such activities and taken to the court will not be prosecuted in shortest period due 
to the court procedure. 
The Pharmacist Council of Nigeria(PCN) as a body in charge of determining the standard of 
knowledge and skill to be attained by person seeking to become registered member of pharmacy 
profession, has tried to establish a mandatory registration which would be required prior to 
practicing as a pharmacist. This would ensure that quack members (to some extent) are given no 
room to practice as they are polluting the profession and render it unprofessional. The council is 
not functioning as it is expected in determining who practices pharmacy in Nigeria. 
_______________________ 
* According to the director-general of NAFDAC, Dr. Paul Orhii (Personal communication, February 25, 
2010) 
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Section 11 subsection A of PCN act, states who shall be entitled to be a pharmacist, “such a 
person should be of good character, fit and proper; has attended a course of training approved by 
the council, or the course was conducted at an institute approve by the council; hold a 
qualification approved by the council; and has undergone the statutory continuous internship 
training for not less than one year under a registered pharmacist…” 
 The non-regulatory bodies include (i) The Pharmaceutical Society of Nigeria, (ii) Nigeria 
Association of General Practice Pharmacists, (iii) Nigerian Association of Industrial 
Pharmacists, and (iv) The Pharmaceutical Manufacturers Group of the Manufacturers 
Association of Nigeria (PMG/MAN). 
 
2.2.2. Drug Distribution Chain in Nigeria 
The drug distribution network in Nigeria is in a state of chaos because it consists of open 
markets, patent medicine stores, and community pharmacies managed by NGOs (Non-
Government Organizations), private and public hospitals, wholesalers/importers and 
pharmaceutical manufacturers. It is a common scene in Nigeria to see medicinal product traders 
who sell cigarettes, kola nuts, and oranges, among other items, in market kiosks, car parking 
wards, and road sides hawking drugs that range from over the counter items to antibiotics. The 
medicines are usually left under the sun in such conditions that could facilitate the deterioration 
of the active ingredients.  
Patent medicine stores are owned by the holders of a patent and medicine vendor license. 
Ordinarily patent medicines should be sold in their original packs. Over the Counter (OTC) 
drugs are the only drugs authorized to be sold by the vendors but they generally sell all types of 
drugs as determined by their financial capability. People have taken the Pharmacy profession for 
granted as if it does not require any skills and training before a person becomes a pharmacist. 
Patients prefer to go to the market[s] directly than pharmacies, so that they can get affordable 
prices and in turn, the drugs they buy often are fake, expired or poor quality. These kind of 
episodes do occur daily and the patients do not know, because they are after cheaper drugs (due 
to countries´ socioeconomic conditions), nevertheless they are being cheated in most cases with 
either expired or fake drugs. In order to maximize their profits pharmaceutical companies prefer 
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to distribute their products via unregulated markets instead of using official routes such as 
hospitals or pharmacies. Thus the drugs may end up in the hands of unqualified personal. 
NAFDAC has therefore; enforced a sustained surveillance at all selling outlets.   Lists of 
identified fake / substandard products are published in Nigerian newspapers and medical revues 
on a routine basis.(Annex 1).The World Health Organization (WHO) has agreed to NAFDAC’s 
plan to carry out a Pan – Nigerian survey to determine the extent of substandard products in 
circulation. New guidelines have been put in place to ensure the importation of genuine drugs 
into Nigeria; these are: 
 Before the registration or renewal of registration of any product, NAFDAC inspectors 
must inspect the production plants in the exporting country. In the case of drugs, the 
factory must be ‘WHO certified’, to ensure Good Manufacturing Practice.  
 In the future, before drugs are imported into Nigeria even after registration, NAFDAC 
approved analysts in the respective countries must conduct a pre-shipment analysis of the 
drugs
24
.  
 
2.3. Analysis in other Countries (Benin Burkina Faso, Cote d´Ivoire, Ghana, Togo) 
The nature and size of pharmaceutical activities in a country determine the type and burden of 
responsibility which the Drug Regulatory Authority (DRA) must bear. Benin Burkina Faso, Cote 
d´Ivoire, Ghana and Togo adopted the WHO guidelines for inspection but do not carry out 
routine inspections abroad mostly due to financial constraints. Thus they have to rely on 
certification and documentation from “well established regulatory authority from abroad. The 
Ghana Food and Drug Board now carries out constant routine inspection of both foreign and 
local production plants; the inspected firms are responsible for inspection fees before and after 
drug registration, this will give them a better overview of activities of drug manufacturers25. 
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Pharmaceuticals trade and professional groups exist in Nigeria and the rest of five countries 
surveyed. Consumer groups have also been formed in these countries. However, their influence 
in relation to drug regulation functions is unclear. The quality of medicines varies greatly, 
particularly in low-income countries, because of poor manufacturing and various uncertainties in 
the distribution system. Regulatory gaps identified in Benin, Burkina Faso Cote d´Ivoire and 
Togo are, the neglected informal sector for medicines supply, over-concentration on pre-market 
rather than post-market monitoring, more attention given to inspection of manufacturing practice 
than of distribution channels. New legislation that imposes GMP standards on domestic 
companies should be implemented rigorously. Standard requirements should be introduced for 
all distributors and registered retail outlets supplying pharmaceuticals in the National healthcare 
system.Visual assessment procedures for accepting medicinal products should follow the steps 
outlined below.   
Examine the products (individual treatments), checking for: 
a. Condition of the containers for the integrity of the primary and secondary 
packaging 
b. Check the overall labelling of the primary packaging, secondary packaging and 
any patient information leaflets for spelling mistakes and damage 
c. Check labels for manufacturing and expiry dates 
d. Check contents for shape and colour consistency 
The outcome of these should be documented and stored and will also help to guide the sampling 
process for laboratory testing. 
The particularity in Ghana is that there were no street vendors along main streets where the 
government started a program for Accreditation of Drug Dispensing Outlet (ADDO)
26
. Through 
this initiative, unlicensed drug vendor are licensed, regulated and trained to understand basic 
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pharmacy ethics in order for them to provide better services to their consumers. Ghana Food and 
Drugs Board in collaboration with the USP’s Promoting the Quality of Medicines (PQM) set up 
a quality monitoring surveillance programme in multiple locations across Ghana. USP is a 
scientific non-profit organization that develops globally recognized standards for the quality of 
medicines. Through the PQM program, USP works in developing countries to help verify and 
improve the quality of medications intended to treat life-threatening neglected diseases such as 
malaria, HIV/AIDS and tuberculosis. Several cases of falsified antimalarial medicines without 
any active substance have been reported in the recent years
27
. Consequently, the PQM 
programme incorporates quality assurance in its medicine regulatory mechanism, but still 
counterfeiters and grey importers of substandard medicines use unofficial channels to outwit the 
existing system. In this context, Ghana’s Food and Drugs Board (FDB) uses GPHF-Minilabs for 
routine drug quality testing with fully-fledged confirmation analysis to improve post marketing 
monitoring. Market monitoring in Ghana is funded by the Medicines Transparency Alliance 
(MeTA) and till to date, two studies of antibacterial, and antidiabetic drug testing have been 
conducted. In both studies, all products tested passed for presence of active pharmaceutical 
ingredients and did not involve counterfeiting. Product failures were however reported in 
specific reference to test of potency (assay of indicated active ingredient) and dissolution in both 
studies. Necessary regulatory interventions to address the problems were implemented.  
The findings underscore the need to maintain collaboration to build Ghana’s national medicines 
quality assurance infrastructure in the interest of public health and safety.  In 2009 the same 
PQM (Promoting the Quality of medicines) program uncovered a counterfeit version of 
Novartis’ Coartem® a widely used antimalarial. A citizen´s alert notified the authorities after 
suspecting the drug he bought might be faked
28
. The discovery of the counterfeits in use at a 
government-run hospital, private clinic, and distributed through many pharmacies has resulted in 
a nationwide recall of all thirteen drugs, including publicizing the names of the outlets where 
they were found. This is intended as a strong deterrent, making pharmacy and hospital 
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procurement personnel more vigilant about their suppliers. The fact that the fake and poor 
quality drugs were so widespread in many areas across Ghana and in many types of outlets 
shows the need not only for continuing surveillance but also for active enforcement of anti-
counterfeiting laws. 
In Togo, there is a necessity for a greater emphasis on public awareness of the problem of 
substandard medicines, law and regulations enforcement on the distributors and local 
manufacturer, in line with internationally-recognized standards, with tough, prohibitive sanctions 
on those who fail to comply. 
The conclusion is that substandards are widespread and also that they affect countries differently. 
The specific problems each individual country has to tackle will depend on the regulatory, 
cultural, and socio-economic policies of that country. As such, some problems can be addressed 
easily, while others require hard thinking, large resources, and national or even international 
cooperation. Substandards are extremely hazardous to the public health since patients consider 
them to be genuine and valid for consumption. The risk to the patient is significant, since 
substandards can have serious adverse health effects and clinical outcomes
29
.This underlines the 
importance of drug regulatory agencies whose role is to prevent substandards from reaching the 
market and to remove those which are already there. Good Manufacturing Practices (GMP) is the 
standard used by regulators to prevent substandards to reach the distribution chains. GMP, as 
defined by the WHO, demands “that products are consistently produced and controlled to the 
quality standards appropriate to their intended use”, whilst “diminishing the risks inherent in 
any pharmaceutical production”30. Quality evaluation primarily provides important information 
on the drug content and secondly identify the cause (if any) of the poor quality. Thus simple, 
rapid and inexpensive assays are necessary to easily set up an on-site quality control unit before 
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large-scale quality evaluation can be performed by a reference laboratory (Green et al. 2001)
31
. 
In ensuring this, the WHO helpfully provides assistance as to guidelines and principles for 
effective GMP. In addition, other important standards set by the WHO include Good Distribution 
Practices (GDP) and Good Storage Practices (GSP). National medicines regulators make such 
standards a mandatory requirement when assessing dossiers for marketing authorisation. A 1999 
report by the WHO found that more than 40% of low income countries had no laws regarding the 
manufacturing and distribution practices of pharmaceuticals, nor did they have inspections of 
facilities carried out by regulatory representatives
32
. GMP ensures the quality of a product 
throughout the whole production process and is not the control of the finished product.The 
quality of drug packaging is key to ensuring that the medicines arrive safely in the hands of the 
patient for whom they are intended.It is not in the interest of the consumer if a product that has 
been produced according to GMP is later stored and distributed under adverse conditions. Where 
a drug is repackaged to improve compliance, the quality of the approved packaging should not 
be jeopardised. Interaction between packaging and drug is possible due to the multiplicity of 
container components and active pharmaceutical ingredients as well as solvents used in a variety 
of dosage forms. The quality of the packaging of pharmaceutical products plays a very important 
role in preserving the stability, quality and efficacy of the drug. It must: 
a. Protect against all adverse external influences that can alter the properties of the 
product, e.g. moisture, light, oxygen and temperature variations; 
b. Protect against biological contamination; 
c. Protect against physical damage; 
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d. Carry the correct information and identification of the product.33 
 Inspection of distribution channels should therefore be given equal emphasis, particularly in 
countries where the drug distribution system has several intermediate levels and the climate 
unfavorable. 
2.3.1. National Procurement and Official Distribution Chains of Pharmaceutical Products 
 in ECOWAS Region 
In a resource limited setting like Sub-Saharan Africa, procurement agencies or medicines 
regulatory authorities usually do not have a full-fledged quality assurance system. Officials from 
national accredited distribution chains (CAMEG, PSP, Procurement board, according to each 
country) in the survey countries (table below) claimed that they only distribute medicines to 
registered drug stores, pharmacies and hospitals. 
Table 1: Central purchasing depots (accredited distribution chains) 
Countries Distributors 
Benin CAMEG
a
, 
Burkina Faso CAMEG
a
, Sonapharm, Cophadix, Laborex 
Cote d'Ivoire PSP
b
 
Ghana Procurement Unit of Ministry of Health 
Nigeria Nigeria 
Togo CAMEG
a
 
a: Central d´Achat des médicaments Essentiels Génériques et consommables médicaux. 
 b: Pharmacie de la Santé Publique. 
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In reality you may find the same medicines distributed by CAMEG, PSP or the national 
procurement Unit on city market stalls, carried by itinerant hawkers along the roads or in 
groceries. Information obtained from workers in local pharmaceutical industries indicate that 
bundled packets of essential medicines are sold directly to some merchants from markets 
because their request is higher than that of official pharmacies and hospitals since they sell lower 
prices compared to pharmacies. Although a number of studies have described informal outlets 
such as shops and kiosks, in regard to their impact on quality assurance, more work is needed in 
this area, since only a few studies incorporate the full range of providers from hospitals to 
informal kiosk, and thus allow an analysis of the substitutability between these different provider 
types. At present there is no information available on the ECOWAS harmonized regulation on 
quality of drugs marketed in West Africa. This study is aimed to evaluate some quality 
parameters of the most commonly used essential drugs. The results will be useful to the ongoing 
harmonization process and especially to the West African Health Organization (WAHO) in 
developing appropriate intervention strategies to ensure that only effective drugs are allowed on 
the ECOWAS market and to promote the public confidence in the quality of the medicinal drugs. 
This will contribute towards the implementation of the Essential Drugs Concept as envisaged in 
the WHO Prequalification program. 
2.3.2. Globalization and its Impact on liberalized Medicine Trade 
With increasing globalization, the linkages between health and trade are becoming more 
complex and affect the performance of pharmaceutical marketing systems. The main concern is 
the need for better and cheaper drugs for health problems in developing countries. 
The liberalization of the pharmaceutical sector has the potential to rapidly spread poor quality 
medicines worldwide. The proliferation of substandards in surveyed countries has a wider 
regional even pan African relevance in regard to patient safety, since the globalization and 
parallel trade of pharmaceuticals means that all medicinal products can now travel across borders 
with greater speed and fewer restrictions, leading to the possibility of such medicines ending up 
in the hands of patients. The health workforce is of strategic importance to the performance of 
national health systems as well as of disease control initiatives. The brain drain from developing 
to industrialized countries is a long-standing phenomenon in the health professions but has in 
recent years taken extreme proportions, particularly in Africa. In reality, this mobility is very 
asymmetrical, to the detriment of less developed countries, which lose not only much-needed 
human resources, but also considerable investments in education and fiscal income. For the Sub-
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Saharan Africa to achieve sustainable progress towards affordable access to drugs it requires 
coherent policies and practices which will assist in overcoming a number of supply- and 
demand-driven constraints; it requires also policy options which suggest how regional 
cooperation could assist in providing affordable access to medicines. 
 
CHAPTER III: Regulatory Factors 
3.1. Regulatory Framework in Survey Countries. 
  The primary aim of drug regulation is the protection of public health. The medicines are not 
average ‘commodities’; they are developed manufactured and marketed according to 
internationally recognized specifications and rules. The medicinal products should meet 
fundamental health needs, and access to essential medicines, according to the World Health 
Organization, is a fundamental human right. Thus, medicines have additional social value. 
Appropriate use of medicines requires a ‘qualified person` to prescribe them and a trained person 
to dispense them appropriately before the consumer takes them. The market for pharmaceuticals 
is therefore not a usual market in economic terms. In this context of concerns about improving 
access to effective and safe medicines, it is imperative to consider how drug regulation ‘fits’ with 
other national policies in relation to health and medicines supply. 
The Model Quality Assurance System (MQAS) was designed by WHO to help its agencies 
(UNICEF, UNAIDS) achieve the goal of a quality procurement system. The model is intended to 
guide them in developing their own quality assurance system. It focuses on four key activities: 
prequalification of pharmaceutical plants, purchase, storage and distribution of pharmaceuticals. 
3.1.1. Prequalification of Pharmaceutical Products and Manufacturers. 
At present, the World Health Organization (WHO) prequalification program is used as a tool to 
enhance the quality standard of medicines circulating in developing countries. This approach 
presents a double advantage firstly, prequalified companies or prequalified medicines quality 
control laboratories are refereed by international donators for medicines purchasing for 
emergency or humanitarian assistance to people in need. It has a positive economic impact on 
selected prequalified companies and concerned countries. Secondly the prequalification program 
boosts competition among local pharmaceutical companies. Nigeria and Ghana are already 
moving towards embracing the WHO prequalification program; Evans Medicals Plc and Swiss 
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Pharma NIGERIA Ltd which are local manufacturers in Nigeria have already submitted an 
expression of intent to the WHO regarding the prequalification program. 
A WHO prequalified quality laboratory (the Mission for Essential Drugs and Supplies) 
established in Kenya is found to help reduce the incidences of quality failures in domestic and 
import supply immensely. It appears that when suppliers are aware that the quality of their 
products is being subject to continuous monitoring, they make sure that they export drugs that 
are of good quality. Fig.10 
The essential medicines list, first assembled by a World Health Organization (WHO) expert 
panel in 1977 and revised every two years to reflect current health challenges, is an inventory of 
medicines that treat pressing local/regional health concerns. Medicines are identified through an 
evidence-based process and quality, safety, efficacy and cost-effectiveness are key selection 
criteria. In close cooperation with national regulatory agencies and partner organizations, the 
Prequalification Program aims to make quality priority medicines available for the benefit of 
those in need. This is achieved through its evaluation and inspection activities, and by building 
national capacity for sustainable manufacturing and monitoring of quality medicine
34
. 
3.1.2. Purchase 
Poor-quality medicines particularly affect lower-income countries, where inadequate 
infrastructure, non-regulated drug outlets, and black market operations make drug quality 
surveys difficult. The Home Management of Malaria (HMM) strategy has been promoted for the 
timely and appropriate management of malaria in Sub-Saharan Africa
35
. Drug Information and 
regulation enforcement are scant. The major strategy under HMM is to train householders to 
better recognize and treat malaria. Unfortunately the drug sellers often lack basic knowledge and 
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are influenced by advertising and profit motives
36
. Most Patients without physians´prescription 
buy drugs for themselves, they are more likely to be adults; more often a child or an adolescent is 
sent to purchase for another person. The most common Patent Medicine Vendors(PMV) in 
Nigeria or Licensed Chemical Shops (LCS) in Ghana behaviours are: selling the requested 
medicine (69%), giving their own suggestions to the customer (30%), asking questions about the 
illness (19%) and providing instructions on how to take the medicine (21%).Apparently PMV 
and LCS are perceived primarily as salespersons (69%). They only fulfilled their duties as a 
health care provider upon request by the patients.Self-medication for presumed bacterial or 
malarial infections with drugs purchased from unofficial drug vendors is a common practice in 
Africa. The essential drugs concept is a strategic policy that enables developing countries to 
improve the availability and access to drugs by the general public. The most important 
component of this concept is the recognition of the fact that only a few drugs are necessary for 
the treatment, diagnosis and prophylaxis of diseases facing the majority of people in a 
community. By concentrating on few essential drugs the meager insufficient resources available 
in developing countries could be well managed and wastage minimized. This policy encouraged 
the compiling of a list of essential drugs tailored to all countries health needs. It was 
recommended that as far as possible the drugs included in the list should be generic drugs (drugs 
which are off patent) as these are usually cheaper (about 30%) and have a proven safety record. 
Furthermore, the essential drugs concept emphasized the importance of encouraging the rational 
use of drugs as a means of minimizing wastages due to the misuse or excessive use of drugs. The 
main pillars of the essential drugs concept are: established safety and efficacy, proven quality, 
constant availability, affordability and rational use. Unfortunately The WHO Essential Drug 
Program has failed in most countries
37
 because of personal financial interests at local, national 
and foreign levels or black market-activities. 
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3.1.3. Storage 
The assurance of the stability of pharmaceuticals marketed in developing countries (most of 
which have tropical climates) is a challenging issue. Poor storage conditions, high temperature 
and high humidity conditions generally enhance chemical degradation and may alter the 
biopharmaceutical properties of the drugs,
38
 as it has been shown for antibiotics such as 
Tetracycline.
39
 There are studies that have shown that high storage temperatures do not adversely 
affect the content of many antibiotics including Penicillins and Tetracyclines.
40
 Moreover, 
interactions may occur when products are exposed (Appendixes 4, 8, 9) at high temperature and 
humidity, consequently reducing the dissolution rate.
41
 Although many substandard 
antimicrobials may contain the appropriate amount of active ingredient, they can have 
suboptimal activity as a result of reduced bioavailability. Examples include Tetracyclines,
42
 Co-
trimoxazole,
43
Pyrimethamine.44The influence of storage at tropical conditions on the stability and 
quality of essential drugs has been one of the concerns of the WHO. Nazerali and Hogerzeil 
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(1998)
45
 conducted a study in Zimbabwe to investigate the influence of storage in a tropical 
climate on the quality of 13 essential drugs. Samples of the same batch of a drug were taken 
from the government medical stores, district hospitals and from health centers. As all studies 
focused on essential drugs suspected of being unstable; the reviewers conclude that, even under 
the most adverse tropical conditions, clinically relevant instability of essential drugs is rare
46
. 
This may suggest that the most likely cause of low quality is to be found during manufacturing. 
The practical implication of this conclusion is that careful selection of suppliers and quality 
control at the entry point of the distribution chain are essential to ensure drug quality. 
Medicine sellers often exhibit a lack of concern about expiration dates and storage conditions, 
especially poor settings and the absence of national control may increase the spread of 
substandard antimicrobials. The challenge for public health providers is to identify and discard 
the poor-quality medicines available on the market. Studies have looked at the expiry status of 
anti-infectives at various points in the distribution chain. For example, Amin et al
47
 audited 
antimalarial products in 880 retail outlets across four districts in Kenya. They calculated the 
remaining shelf life for 2,167 unexpired antimalarial products audited during the survey. The 
authors report that there was sufficient remaining shelf life for most antimalarial drugs with a 
median of 46 months for Amodiaquine®, 30 months for Sulfadoxin - Pyrimethamine (SP), 22 
months for Chloroquine® (CQ), 17 months for quinine and 12 months for products containing 
Artemisinin. Overall, approximately 90% of products were within their labeled shelf life. In this 
study, the basic storage conditions for Antimalarials in the audited retail outlets was also 
evaluated using a simple set of indicators: stored off floor, out of direct sunlight, in a dry area 
and away from direct sunlight. Over 97% of the products audited satisfied these conditions. 
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The minimum standards which should be considered when handling medicines are*: 
a) Materials for manufacturing and pharmaceutical products should be handled and stored in 
such a manner as to prevent contamination and mix-ups. 
b) Storage areas should be of sufficient capacity to allow for orderly storage.  
c) Storage areas should be designed or adapted to ensure good storage conditions. In 
particular, they should be clean and dry and maintained within acceptable temperature 
limits. Where special storage conditions are required on the label (e.g. temperature, 
relative humidity), these should be provided, checked, monitored and recorded.  
d) Materials and pharmaceutical products should be stored off the floor and suitably spaced 
to permit cleaning and inspection. Pallets should be kept in a good state of cleanliness. 
e) Storage areas should be clean, and free from accumulated waste and vermin. A written 
sanitation programme such as SOP (Standard Operating Procedure) should be available 
indicating the frequency of cleaning and the methods to be used to clean the premises and 
storage areas. There should also be a written programme for pest control. The pest-
control agents used should be safe, and there should be no risk of contamination with the 
materials and pharmaceutical products.  
f) Precautions must be taken to prevent unauthorized persons from entering storage areas  
g) Materials and pharmaceutical products should be stored in conditions which assure that  
their quality is maintained, and stock should be appropriately rotated. The “first 
expire/first out” (FEFO) principle should be followed. 
h) Broken or damaged items should be withdrawn from usable stock and separated. 
i) Storage areas should provide adequate lighting to enable all operations to be carried out 
accurately and safely. 
 
_______________________ 
* Personal information from GMP Module at WAHO Training for Local Manufacturers and Medicines 
Regulatory Authorities in ECOWAS Region. Lagos October 2010 
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However, it is often unclear whether a poor-quality drug is the result of deliberate counterfeiting 
or substandard production, transport, and storage problems
48
.Lack of Good Manufacturing 
Practices (GMP) is common in local pharmaceutical industries in most developing countries 
because of many hurdles such as frequent electric power cuts and shortage of water. 
3.1.4. Distribution 
Most developing countries still lack their own quality assurance facilities to assess the quality of 
pharmaceutical products they import. Major exporters among developing countries such as 
China, India, and Pakistan export to other low- and middle-income countries. In many 
developing countries an unfortunate combination of two factors exists: On one hand, the 
predominance of imported finished medicine products and on other hand the lack of adequate 
analytical services and appropriate human resources. Regulated Imports by low- and middle-
income countries come mainly from industrialized countries. Parallel trade is the legal 
importation of a patented drug without the authorization of the patent holder. The main driver 
behind parallel trade is the variation in the manufacturers’ drug prices across markets. Importing 
occurs from countries with a low drug price relative to the price of the same drug in the 
importing country and where the price difference is sufficient to cover the costs of transport, 
registration, relabeling/repackaging, creating and inserting leaflets according to national 
requirements. Parallel distributors, brokers and their allies aggressively seek to avoid detection. 
They exploit weaknesses in border control whenever governments try to promote world 
commerce by reducing border controls. Pharmaceutical companies manufacture drugs and 
provide them to distributors or move round the pharmacies, various hospitals and other relevant 
institutions for onward use. The problem or the failure of pharmaceutical companies is that, 
instead of focusing on pharmacies, they prefer to reach the open unregulated market purposely to 
maximize their profit. Drugs dealers in the markets represent some manufacturers and other sole 
agents selling drugs; these dealers are literate, illiterate or educated but not educated in health 
related fields.  
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 Unqualified drug sellers offer alternative drugs when the prescribed drugs are out of stock or 
refill prescriptions without consulting the prescriber. The majority of drug sellers or licensed 
chemical stores are less aware of the detrimental effects of inappropriate antibiotic use. Health 
authorities should endeavor to set up their own drug regulatory systems based on legislation and 
regulations. A study on drug sellers’ knowledge in Dar es Salam-Tanzania by Massele et al. 
1993 revealed that only 20% of vendors knew the correct dose of Chloroquine®. Pharmacy 
technicians in Thailand prescribed Rifampicin for Urethritis and Tetracycline for young 
children
49
. Indeed, the proliferation of substandards in surveyed countries has a wider regional 
even pan African relevance in regard to patient safety, since the globalization and parallel trade 
of pharmaceuticals mean that medicinal products can cross borders with greater speed and fewer 
restrictions, leading to the possibility of such medicines ending up in the hands of patients. 
The liberalization of the pharmaceutical sector has the potential to rapidly spread poor quality 
medicines worldwide. In common practice, more than half of all disease episodes in Sub-Saharan 
Africa (SSA) are initially treated with home management (self-medication) by private providers, 
mainly through the purchase of drugs from shops and drug peddlers, before consulting an official 
health care center. This practice leads to misuse of medicines such as overdosing. Drug shops 
generally stock a range of medicines for minor ailments, basic first aid supplies and toiletries. 
They have been tolerated by national health authorities in many developing countries to provide 
a suitable entry point for government intervention to improve retail sector treatment, as they 
form an established network in both urban and rural areas, and their staff generally have some 
medical training or experience (Goodman et al. 2004)
50
. Studies in six Latino American 
countries indicate that in countries with little regulation, substantial misuse of antibiotics exists
51
. 
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Non-governmental organizations working in developing countries also use drug tenders without 
applying minimum quality assurance procedures (European Commission Humanitarian Aid 
Department 2006)
52
. The supply of good quality essential medicines is undoubtedly one of the 
prerequisites for the delivery of healthcare. However, there is widespread concern that drug 
shops frequently flout pharmaceutical regulations and prioritize profit-making over good 
distribution practice, leading to poor quality care, unsafe practices and behavior that encourage 
the circulation of substandard and counterfeited medicines. 
3.2. Ineffective Drug Regulation and related Consequences 
 More than a decade after the World Health Organization (WHO) has called member states to 
establish and /or enforce regulations that ensure good uniform standards of quality assurance for 
all pharmaceutical products manufactured in, imported to, exported from, or in transit through 
their countries, still, there are several reports on the circulation of substandard and counterfeited 
pharmaceutical products in the markets of Sub-Saharan Africa. A study in Nigeria (Taylor et al. 
2001) found that almost half of the randomly sampled antibiotic and antiparasitic drugs did not 
comply with set pharmacopoeial limits
53.
 The illicit marketing of medicines is still rife in 
developing countries. The existence of substandards, degraded medicines and counterfeits on 
markets can be indicative of the same or similar problems of ineffective drug regulation and 
related law enforcement. The use of substandard and counterfeit drugs is not only a waste of 
resources, but may also threaten the health and lives of those who take them. Examples include 
the sulfanilamide incident that led to the deaths of 107 children in the United States of America 
in the mid-1930s
54
 and the thalidomide disaster of the 1960s which caused birth defects on 
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children in Germany
55
. More recently, Diethyleneglycol contamination in drug preparations, 
such as Paracetamol, has led to multiple tragedies in Haiti and India
56,57
. In Niger, fake 
meningitis vaccines, administered during an epidemic in which more than 26700 people had 
contracted the disease, led to the deaths of 2500 peoples
58
.Therefore, harmonized action is aimed 
at encouraging rigorous regulatory control of medicines; more action is now needed to encourage 
countries to establish standards which ensure that products meet the necessary, internationally 
accepted criteria of quality, safety and efficacy. 
In Africa, illicit drug marketing is not limited to illegitimate ambulatory drug sellers or stall 
owners in the marketplace; it is common to find cheap and ineffective drug copies existing next 
to the original or generic brand in an official pharmacy, or supplied by the same wholesalers. 
Many dealers break the law by dispensing prescription-only drugs over the counter or providing 
counterfeit replacements to patients with insufficient money to purchase the original. It is 
therefore very important to implement measures against abusive use of pharmaceutical products. 
The concerns expressed are legitimate. However, with respect to the possible adverse clinical 
effects of substandard drugs, the reasons why they are poor quality must be clarified. The most 
obvious reasons are poor manufacturing practice, inadequate quality assurance or possible 
decomposition of active ingredients. The latter is plausible when drugs are exposed on market 
stalls for weeks or even months under conditions conducive to chemical degradation of active 
ingredients, particularly in tropical countries (Appendixes 9, 11). 
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The problem of substandard drugs is more pronounced in developing countries and some factors 
responsible for this can be identified. One is that in less resourced countries there are few 
functioning drug regulatory authorities. An assessment on the performance of regulatory 
functions conducted by the WHO in 26 African countries identified some flaws in medicines 
regulatory environment.
59
. In fact, most National Medicines Regulatory Authorities (NMRA) 
lacked sustainable funding. Another concern is that, there is a universal shortage of qualified 
staff and operational resources. Quality Management System that covers regulatory elements, 
procedures and trainings to keep staff abreast of new technology and science do not exist, also 
specific measures to avoid conflicts of interest are generally absent. 
 
Source: Assessment of medicines regulatory systems in Sub-Saharan African countries Page 11 - 
WHO/EMP/QSM/2010.4 Accessed on October 22, 2011 
The lack of systematic quality control and a non- regulated drug distribution system create an 
environment favorable for introducing low-quality drugs. Structures exist to inspect local 
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medicines production sites for compliance with national requirements; but the coordination of 
such inspections was not well established; the insufficient of qualified inspectors (Fig. above), 
the lack of transport and communication means severely limited the number and quality of 
inspections conducted. In some of the surveyed countries the applied guidelines were not in line 
with Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP). According 
to the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) about 
7% of all drugs being sold around the world in 1992 were of poor quality (counterfeited or 
substandard). The problem is worldwide and occurs both in rich and poor countries. The impact 
is alarming if consideration is given to the increased treatment costs, reduced productivity, 
patient suffering and possible development of resistance by susceptible microorganisms. 
The main concern is about their quality and efficacy with regard to their distribution, handling 
and storage conditions. There are three main categories of poor-quality medicines.    
A counterfeit medicine is “deliberately and fraudulently mislabeled with respect to identity 
and/or source. Counterfeiting may include products with the correct ingredients or with the 
wrong ingredients, without active ingredients, with insufficient active ingredient or with fake 
packaging”.60 Counterfeit drugs do not meet quality standards and do not declare their real 
source for the purposes of fraud. They may be generic or innovative. 
Substandard medicines (also called out-of-specification (OOS) products) “are genuine 
medicines produced by legitimate manufacturers that do not meet the claimed quality 
specifications. For example, they may contain less (or more) active ingredient than written on 
the package. This may not be an intention to cheat, but may be due to problems with the 
manufacturing process”.61 They are an inevitable consequence of inadequate local regulation of 
the pharmaceutical industry and the lack of Good Manufacturing Practices (GMP) facilities in 
many ‘developing’ countries. Poor compliance with GMP standards can lead to substandard 
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production. This may be accidental (such as human error) or the result of insufficient resources 
(expertise, appropriate manufacturing infrastructure, or human and financial resources). Other 
deliberate causes are often ignored or underestimated. 
Degraded medicines “may result from exposure of good-quality medicines to light, heat, and 
humidity. It can be difficult to distinguish degraded medicines from those that left the factory as 
substandard, but the distinction is important as the causes and remedies are different”.62High 
temperature and humidity, and poor quality assurance during the manufacture of pharmaceutical 
products in less-developed countries could lead to degraded medicines. 
The WHO has been tracking and documenting the incidences of substandard drugs. The records 
show that problems of substandard and counterfeit drugs are increasing as 50% of all reported 
cases occurred in the period 1993 to 1997. Most of these incidences (70%) were reported in 
developing countries. The report identifies the causes of the poor quality of drugs: in about 50% 
of all cases the formulations did not contain any drug (active substance), 20% contained the 
wrong active ingredient and 10% the wrong amount of the active ingredient. Only in 5% of the 
reported incidences did the drugs contain the right active ingredient in the correct amounts, but 
were judged substandard by failing other quality tests. Antibiotics represented the class of drugs 
with the largest number of incidences (60%) of counterfeiting (WHO, 2000), posing an even 
greater health risk as substandard anti-infective drugs may lead to selection of resistant strains of 
microorganisms, reducing the achievements made so far in combating infectious diseases. 
Substandard drugs are not found only in developing countries, in developed countries where the 
drug regulations are strictly enforced; some incidences of substandard drugs on the market have 
been reported. However, there is a higher prevalence of substandard drugs in developing 
countries as less stringent quality control measures are in place in these countries. In Kenya, the 
quality of metronidazole products available on the market was evaluated; all products conformed 
to the United States Pharmacopoeia (USP) specifications. However two formulations failed the 
dissolution test as they released only 46.8% and 45.8% of drug in 40 minutes (Kibwage et al., 
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1991)
63
 whereas a minimum of 80% drug release within 40 minutes is required. Kibwage et al. 
(1992) reported that about 45% of the drugs sampled on the Kenyan market and analysed at Daru 
(Drug analysis research Unit) quality control laboratory on a routine basis, were of substandard 
quality in terms of the drug content
64.
 In 1994, Roy reported on the existence of substandard 
formulations (37 out of 137) in Bangladesh, some of which had been found to be of acceptable 
quality by the local Drug Regulatory Authorities
65
.  Shakoor et al. (1997) evaluated the quality of 
pharmaceuticals on market in Thailand and Nigeria
66
; the sampled drugs were Antimalaria and 
antibiotic formulations that are the most frequently used in these countries. The studies revealed 
that 36% of the samples from Nigeria and 40% from Thailand did not comply with the British 
Pharmacopoeia standards. The content of the active ingredient in some of the samples was 
marginally outside the official limits. Three of the substandard samples from Nigeria (2 
Chloroquine and 1 Amoxicillin) and 3 from Thailand (all Chloroquine) were fakes. Since the 
authors could not detect impurities or degradation products (except from an 
Ampicillin/Cloxacillin suspension), they suggested that the major reason for substandard drugs 
in the developing countries was poor manufacturing practices on the part of the suppliers. Gomez 
et al. (1998) reported on the differences in assay results of Antimalaria drugs analyzed by the 
quality control laboratory of the Institute of Drug Control in Vietnam
67
; some of the drugs that 
had passed the quality tests in the quality control laboratory, failed when independently assessed 
by a World Health Organization accredited laboratory.The finished pharmaceutical products 
manufactured under the specified conditions as per the GMP should be able to meet 
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 the specification as defined in internationally accepted monographs. It is estimated that only 
30% of the developing countries have an established and functioning drug regulatory authority 
(WHO, 2000)
68
. Nevertheless, most of the regulatory authorities have not established quality 
control laboratories. Even when these are available, they lack proper equipment and human 
resources to perform the work properly and/or to monitor the quality of the drugs on market. In 
some cases they have not instituted Good Laboratory Practices (GLP), which is required for the 
reliability of the analytical results. Taylor et al. (2001) evaluated the quality of 581 formulations 
of 27 different drugs from 35 urban pharmacies in Nigeria; the potency of 48% of the samples 
did not comply with the USP or BP pharmacopoeia specifications for drug content. Most of the 
failed samples had a drug content that was marginally below the pharmacopoeia limits.  
3.3. Obsolete Drugs in Developed Countries and the Prevalence of Substandards 
The standard of living contributes to the prevalence of substandard drugs in developing countries. 
In more than 36 developing countries, including many ECOWAS member countries, the average 
annual per capita expenditure on drugs by the population is less than one US dollar. This low per-
capita consumption is an indicator for the inability of the people to afford basic drugs from 
regulated outlets.  Drugs necessary for the treatment of certain tropical diseases have begun to 
disappear from the market because they are commercially unprofitable. Many of these drugs were 
discovered in the 1950s and1960s or earlier and are rarely used in wealthy countries. An example 
is seen in the effort to treat epidemic bacterial meningitis, caused by Neisseria Meningitides 
(refers to Meningococcus, a bacterium that can cause Meningitis), which is rampant in Sub-
Saharan Africa. The efficacy of treatment with Chloramphenicol in oily suspension (1 
intramuscular injection repeated after 48 hours) for bacterial meningitis is comparable with the 
traditional treatment with Ampicillin (intravenous injections 4 times daily for 10 days). The lower 
cost of Chloramphenicol in oily suspension which represents one tenth of the cost of the 
Ampicillin treatment in addition to its simple administration makes it particularly suitable to the 
precarious conditions in developing countries. In Nigeria in 1996, for example, more than 100 000 
cases of Neisseria Meningitidis infections were reported. However, production and availability of 
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Chloramphenicol in oily suspension are no longer guaranteed because it is no longer a first-line 
agent for any infection in developed nations. Oily Chloramphenicol is recommended by the World 
Health Organization (WHO) as the first-line treatment of Meningitis in low-income countries, and 
appears on the WHO essential drugs list. It was first used to treat Meningitis in 1975 and 
numerous studies since have demonstrated its efficacy. It is the cheapest treatment available for 
meningitis (US$5 per treatment course, compared to US$30 for Ampicillin). Non-professional 
importers and less equipped local manufacturers use such opportunities to substitute the unmet 
needs with poor quality or substandard versions of Chloramphenicol. In developing countries, 
drugs are known to consume more than 40 to 60% of the total public and private spending on 
health, while in the developed countries it is limited to about 15 to 20% (WHO, 2000). Among the 
major reasons for these differences is the increased frequency of contracting diseases in the 
developing. Pharmaceutical retailers in Sub-Saharan Africa include a very limited number of 
formal pharmacies, and numerous general stores that sell a range of groceries and household 
products. Medicines are also sold by small drug shops in many ECOWAS (Economic Community 
of West Africa States) areas. What is amazing is that some of these illicit drug stores are closed by 
city council officials not for non-conformity to the medicines storage standards or regulatory 
requirements but for not paying taxes. This means that the national authorities recognize the 
existence of such illegal and non-regulated outlets but turn eyes closed. However, the question 
how medicinal products reach illegal vendors remains without answer. In the center of market 
places and bus stations, you come across many illegal drug store handlers. One of the most 
rational options was to adopt the World Health Organization’s (WHO) essential drugs concept. 
 A number of recent initiatives have been established to address the problem; most notably the 
importance of encouraging the rational use of drugs as a means of minimizing wastages due to the 
misuse or excessive use of drugs. Regular surveillance of the quality and bioequivalence of 
pharmaceuticals on the market in Finland has identified amongst different brands of erythromycin 
tablets, one with a very low bioavailability (Venho et al., 1987). This brand had to be withdrawn 
from the market. However, there is more prevalence of substandard drugs in the developing 
countries in general as less stringent quality control measures are in place in these countries. The 
peddlers or itinerant hawkers procure the medicines in blister without package leaflet from 
merchants in markets and sell them from house to house or in rural areas. The peddlers are the 
only distributors who accept credits, this means medicines are sold on the local market day and if 
the consumer has no money, he may reimburse the next market day (periodically one or two 
market day per week). Other procurement facilities are Caritas and religious associations which 
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have easy access to procure medicines from pharmaceutical factories with the aim to redistribute 
them through hospitals with health care professional staff. There, free distributed medicines are 
stolen by scrupulous staff and allied patients who resell them to merchants in markets at reduced 
price. Usually, the seller and the customer discuss only about the price and expiration date; other 
quality aspects are not relevant in such transactions. 
 
3.4. Chaotic Drug Distribution Network 
Drug distribution network in surveyed countries consists of chaotic open markets which act as 
major sources for procurement, medicine stores, pharmacy outlets, private and public hospitals, 
wholesalers/retailers and local pharmaceutical manufacturers, agents or representatives of 
foreign suppliers. The result of this chaotic drug distribution makes drug monitoring very 
difficult. In addition, it gives room to drug hawking in buses, kiosks, by illiterate vendors whose 
aims are solely profit oriented. The medicines are left under conditions that may facilitate the 
deterioration of the active ingredients (Erhun, 2001)
69
. Medicines are sold just like any other 
goods of the trade (Appendixes.1, 11). Poor drug regulation which affected the pharmaceutical 
sector over years, helped the raising of drug markets which are not registered premises and are 
well established all over the region. Most of the drug wholesalers and importers supply drugs to 
these open drug markets because they make more profit from there. Consumers purchase such 
products with a hope of obtaining the genuine one, and most of the time these drugs are 
distributed through unauthorized channels
70
.There is always demand for cheap drugs due to 
easier access, better affordability and sometimes better availability as compared to public health 
facilities. Hence illegal traders will quickly fill the gap in supplies. 
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 According to Brains (2004: Figures 2a, 2b) drug distribution chains in resource limited countries 
consist of different actors within the legitimate supply chain and the illegitimate supply chain. 
The legitimate supply chain consists of original products from the designers down to consumers; 
and is regulated and monitored at all levels. The products are then bought by wholesalers for 
distribution, from there the authorized retailers buy and dispense to the consumers. Moreover, if 
the product does not match its predetermined specifications it will be removed (´´recalled´´) from 
the market. The illegal supply chain is made up of dubious distributors and their allies who can 
copy other products and present them as original. The product design is faked with the aid of 
fake manufacturer in criminal organization who distributes the drugs on local markets and via 
internets. The products go to an unauthorized retailer who buys it for profit purposes even when 
he knows the source is suspicious, dispenses the fake product to an innocent victim. 
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, 2010 
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CHAPTER IV:  Factors influencing the Pharmaceutical Marketing 
4.1. Factors influencing the Proliferation of Substandards and Counterfeits 
4.1.1. Medicines Price 
The high cost of pharmaceutical products limits access to treatment. Drug prices should vary 
according to some measure of national wealth and affordability. The agreement at World Trade 
Organisation (WTO) ministerial conference in Doha to minimise the adverse effects of patent 
protection on public health has increased the relevance of differential pricing as a means of 
improving access to patented medicines in low income countries
71
. Income per capita and the 
cost of medicines are key factors affecting demand and thus influence the choice of   medicine 
provider, the choice of drug, the quantity and dose purchased. In less resourced countries like 
Sub-Saharan Africa, cost is frequently mentioned as a reason for not using health facilities 
(Williams and Jones 2004)
72
. There are higher chances for fake drug proliferation when 
medicine prices are high. Scrupulous distributors take advantage of consumers who cannot 
afford high priced quality drugs by supplying them with cheaper substandard or counterfeit 
drugs. The treatment costs are generally cheaper at drug shops because there are no consultations 
or laboratory fees and small quantities like a single blister or two-three tablets/capsules of drugs 
can be purchased (Adome, Whyte and Hardon 1996)
73
. The majority (90.2%) of Nigerians 
cannot afford good medicines as they live below an income level of US 2$ a day
74
. The baseline 
survey also showed a low availability of essential medicines in health facilities. Only 46% of 
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essential medicines were found in the health facilities
75
.  Governments and local pharmaceutical 
industries face the dilemma of “make or buy?” Often, a politically strong domestic industry will 
persuade a government to purchase locally manufactured pharmaceuticals, even if it is more 
costly than purchasing imported drugs. These decisions have important implications for 
pharmaceutical industrial policy and for health care policy. In the Philippines, for example, the 
senate has approved a bill called affordable medicines; act that will help dumping the prices of 
drug so that it can be affordable and their domestic pharmaceutical companies may have a larger 
sale in their drug market. In addition, it will help reduce the incidence of imported fake drug into 
the country
76
.  
4.1.2. Demand Exceeding Supply and Consumer Awareness 
The supply and distribution of medicines are a fundamental aspect of the success of any health 
system. Public supply chain in Sub-Saharan Africa is afflicted by inadequate financing and a 
devastating reduction in the healthcare workforce; the formal sector is generally limited to urban 
areas.  Well-trained health personnel are scarce and cannot serve the entire population, especially 
in rural areas. Faith based and other non-governmental services supplying health care handle less 
than 15% of a country's pharmaceutical needs. Irrational use of medicines is a major problem in 
the region. It is estimated by WHO that more than half of all medicines are prescribed, dispensed 
or sold inappropriately and that half of all patients do not take them correctly. Irrational use of 
medicines covers instances where there is unnecessary prescription of drugs, especially 
antibiotics, prescription in wrong dosages, inappropriate self-medication, and under dosing or 
over dosing. This occurs due to a lack of awareness and knowledge among patients. This 
increases the financial burden on the poor, who often have to purchase the medicines out of own 
pocket. There is a huge gap in access to medicines in rural area. Disruptions in the supply of 
medicines undermine health outcomes as supply chains have an impact on the availability, cost 
and quality of medicines. People are encouraged to buy from unofficial distributors because 
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drugs often are not available in government hospitals. Consequence, unqualified drug sellers 
offer alternative drugs when the prescribed drugs are out of stock or refill prescriptions without 
consulting the prescriber
77
 The following figure shows all probable factors influencing the 
proliferation of unwholesome medicines in resource limited countries. The consequences of the 
use of such medicines may vary from therapeutic failure to the occurrence of serious adverse 
events and even death. Proper drug quality monitoring, enforcement of laws and legislation, an 
effective and efficient regulatory environment, as well as awareness and vigilance from 
stakeholders can help tackle this problem.  
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Fig 3: Factors influencing the Proliferation of unwholesome Medicines in Sub-Saharan Africa 
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PART 3: METHODS AND MATERIALS 
CHAPTER V:  Methodology 
5.1.  Objectives of the Study 
This study is aimed at evaluating the regulatory flaws and some quality parameters of the most 
commonly used essential drugs. The results will be useful to the ongoing harmonization process 
and especially to the West African Health Organization (WAHO) in developing appropriate 
intervention strategies to ensure that only effective drugs are allowed on the ECOWAS market 
and to promote the public confidence in the quality of the medicinal drugs. This will reinforce 
the implementation of the Essential Drugs Concept as envisaged in the WHO guidelines. 
As a result, this will form an important supplement appeal for awareness to what has already 
been explored in country specific manner in the previous publications. Also this paper assess the 
problems caused by substandard drugs and the effectiveness of regulations designed to prevent 
such medicines from entering the harmonized medicine´s market in the ECOWAS region. 
With aim to find out if counterfeit medicines/substandards are due to manufacturing deficiency 
or deliberated misleading.  
5.2.  Analytical Methods 
Nowadays, the first step in detecting counterfeit drugs is to compare the physical appearance and 
text on packets, leaflet inserts, and blister packs of suspected samples with those of known 
genuine products. However, with increased counterfeiter sophistication, this careful visual 
inspection is not sufficient to distinguish between fake and authentic drugs. It must therefore be 
followed by chemical analysis, includes High-Performance Liquid Chromatography (HPLC), 
considered as the gold standard analytical method in drug analysis, but also with simple in-field 
assays [e.g., colorimetric test and Thin-Layer Chromatography (TLC)] or more advanced 
laboratory techniques [e.g., Mass Spectrometry (MS), vibrational spectroscopies (Raman or IR), 
and nuclear magnetic resonance (NMR) spectroscopy]. 
We used information gathered during research journey in some ECOWAS countries, interviews 
with local stakeholders. Questions concerning regulation and illegal behavior are inevitably 
highly sensitive and there was a risk that medicine shop staff would decline to participate or fail 
to provide full and truthful answers. Sensitive questions on regulation were asked towards the 
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end of the interviews; as a result, no drug stores refused to participate in any data collection 
(selling of medicines) activities. Literature from WHO home page, NAFDAC home page, 
Google and Pubmed were also consulted. 
The major limitation to the thesis is the social and financial situation in which I had to complete 
the work, together with the distance from the concerned region (Sub-Saharan Africa) and my 
residence country (Germany) had impacted on the volume of collected information. 
The analytical methods permit a qualitative and quantitative description of the chemical 
composition of a drug. Therefore they can be readily used to not only identify poor quality 
medicinal products but also to distinguish between counterfeit, substandard or degraded drugs. 
In the present dissertation, visual inspection (organoleptic test), X-ray diffraction, Rama 
spectroscopy, and the HPLC have been used for chemical analysis of the collected samples. 
Table 2: laboratory methods of analysis to investigate medicines quality and their respective advantages and 
disadvantages. 
Separation Technique Pros Cons 
X-ray diffraction (XRD) Enables identification of inorganic 
and organic excipients, and crystal 
form 
Extremely high cost, skilled 
Operator required. Not all organic 
Components may be detected. 
Raman spectroscopy Can identify unknown Active 
Ingredients and verify quality. In 
many cases, may work through 
packaging Very sensitive. Portable 
Requires relatively pure sample 
Excipients may fluoresce, making 
measurements difficult 
Costly, but less expensive than 
NIR 
High Pressure Liquid 
Chromatography (LC) 
(also referred to as 
HPLC) 
One of the most widespread 
pharmaceutical analysis techniques. 
Able to identify compounds by 
spectrum database comparison. 
Offers peak purity assessment 
Requires solvents, expensive 
columns, and trained  personnel. 
Cost depends on detector used 
5.2.1. Organoleptic Test 
The first step in identifying potential substandard/counterfeit medicines is the careful visual 
inspection of the product, its packaging and labeling. Through a close observation of each 
pharmaceutical preparation, detailed organoleptic descriptions of the outer containers, the 
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blisters, the package inserts and the dosage forms (capsules or tablets) are checked for each 
sample. Moreover, other important details such as the manufacturing and expiry dates, the 
registration, the batch/lot number, the indications, cautions and the storage conditions are read. 
The following examples are visual inspection done on collected antibiotics during my research 
journey in some West African countries. 
Tetra250®: Active Substance: Tetracycline HCL Capsules 250mg. 
Manufacturer: Sprukfield (UK) SARL BP. 1218 Rue 23 Zone Portuaire, Lome (Togo). 
MainOffice: First Floor. Kirkland. Peterborough Road HA1 2AX.UK. www.sprukfield.com. 
Procurement place: Lome (Assigame) Togo 
Procurement date:  March 9
th
, 2010 
Concerns: 
No packaging leaflet attached. On the blister no instructions concerning side effect, dosage is not 
specified; it is written: (as directed by the physician), no indication for the user on out packaging. 
Cipro 500mg USP®: 
Manufacturer: ZMC Hamburg GmbH, Germany. ZMC HAMBURG GMBH GERMANY is an 
oversea subsidiary of Zhejiang Medicine & Health Products Export & Import Co., Ltd., 
http://www.sinoheal.com/ 
Procurement place: Assiganme Market in Togo. 
Procurement date: March 9, 2010. 
Concerns: 
The package leaflet comprises many mistakes such as dosage form: ciprofloxacin. This should 
be tablet, capsule, injectable, or liquid. 
Cipromax fort 500®: 
Ciprofloxacin Tablets USP. 
Manufacturer: Greenfield Pharmaceutical, Jiangsu (China) 
Procurement place: Assiganme Market in Togo 
 METHODS AND MATERIALS 
 
58 
Procurement date : March 9, 2010. 
Concerns:  
False translation of the instructions on the package (tenir tous les medicaments à portée [should 
be ‘’hors de portée’’ des enfants); 
Poor legibility (type size under 7) of the package leaflet (readability). 
RGI Doxycycline 100mg capsules®: 
NAFDAC Reg.No.A4-2490. 
Manufacturer: Richy Gold International Ltd. 103c Amuwo-Odolin Industrial Scheme Oshodi-
Apapa Expressway, Lagos (Nigeria). 
Procurement place: Assiganme Market. 
Procurement date: March 9
th
, 2010. 
Concerns: 
It was mentioned on the package: Indication: Please refer to the leaflet although there was no 
leaflet in the package. 
“Store in a cool, dry and dark place” was translated “Entreposer dans une place fraiche et sèche”. 
This is not the correct translation. 
5.2.2. Mini lab Test (Visual inspection and disintegration test) Table 1 
Quick release tablets and capsules must pass disintegration test; they should disintegrate in water 
at 37°C in less than 30minutes. It´s a major defect, if a product doesn’t pass this test* 
 
 
 
________________________ 
* A concise Quality control Guide on Essential Drugs and other Medicines.Vol.1 on colour reaction tests 
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5.3. Use of Advanced Analytical Techniques: 
5.3.1. X-ray diffraction (XRD): 
Definition: XRPD (X Ray Powder Diffraction) is used to detect and quantify crystalline 
impurities, to determine the crystallite size of a compound analyze and optimize final dosage 
forms; it detects and analyzes the used fillers in capsules/tablets. 
The following spectrums are the outcome of the application of X-ray diffraction at the 
pharmaceutical Technology of the institute of pharmacy –university of Bonn. 
5 10 15 20 25 30 35 40
2Theta (°)
0
100
400
900
1600
2500
I
n
t
e
n
s
it
y
 
(
c
o
u
n
t
s
)
Amoxicillin BP 500 KAV
5 10 15 20 25 30 35 40
2Theta (°)
0
100
400
900
1600
2500
In
te
n
s
it
y
 (
c
o
u
n
ts
)
 
 
Figure 4:   X-ray diffraction applied to different Amoxicillin tablets 
Amodex® 500mg; 
Batch.183. Manufacturer: 
Ciplapharma              
Cote d´Ivoire 
Amoxihexal ®750mg 
Hexalpharma Germany 
(Comparator) 
Amoxicillin BP 500 KAV ® 
marketed in Benin, Cote 
d´Ivoire, Togo 
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5.3.2. Raman Spectroscopy : 
5.3.2.1.  Experiment Tools 
Instrument 1: TruScan Raman Analyser 
Definition: The TruScan handheld Raman analyzer is an instrument for identity tests in 
pharmaceutical quality control and for counterfeit testing of pharmaceutical products. It is a non-
destructive technique that reveals information about the chemical composition and 
crystallographic structure of manufactured and natural materials. 
 It compares the Raman spectrum of a sample with a stored spectrum of a reference sample with 
proven identity. 
 
 Instrument 2: (First defender RM) A handheld Raman spectrometer for forensic investigations.  
It has an on-board spectral library of about 8.500 chemical substances. Most of our samples gave 
good Raman spectra that could be analyzed. In most cases the Active Pharmaceutical Ingredient 
(API) was identified in the product with comparison with available comparator. 
In both methods sample testing had to be limited to samples for which reference spectra / 
substances were available. 
Samples tested using First defender RM from Servantech (see Table 3 in section5.3.2.2) 
 
 
 
                                                 
 
 Introduction to Raman spectroscopy. Available from www.ahurascientific.com. Internet; accessed on 
June 27th, 2010 
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5.3.2.2. Experimental 
Raman spectroscopy is a kind of vibrational spectroscopy that uses a laser for vibrational 
excitation of the sample. Because it works in the visible spectrum (from the laser wavelength of 
785 nm to approximately 1000 nm) it is able to measure through transparent packaging like glass 
or transparent plastics. For samples like tablets or capsules the Raman scattering signal comes 
from the surface – therefore coated tablets and capsules have to be opened to measure the active 
ingredients. 
The measurement mode had to be chosen according to the kind and packaging of the sample:  
Table.3: Measurement mode and related pharmaceutical forms 
Sample Measurement 
Uncoated tablet, transparent blister Measured directly through the blister 
Uncoated tablet, non-transparent 
blister 
Measured directly, after opening the blister 
Coated tablets Measured directly, after breaking the tablet or removing the 
coating 
Capsules Measuring of the capsule content in a glass vial 
 
 
TruScan Handheld Raman  Analyzer 
 
 
 
 
First Defender RM Raman Analyzer (for 
forensic investigations) 
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A typical measurement took a few seconds and mostly less than 1 minute (including spectral 
analysis). Only for a few samples showing strong fluorescence the measurement took longer – in 
some of these cases the spectrum could not be interpreted because fluorescence was much 
stronger than the Raman signal. Fluorescence can be a characteristic of the original product, but 
may also be caused by impurities, e.g. in counterfeits or degraded products. 
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5.3.2.3. Findings 
Table 4.Results of the Raman measurements of some collected samples: 
Product, Batch/ 
Expiration date. 
Manufacturer Appearance, 
Packaging 
Spectrum Identity test 
ERY
®
 500mg 
Batch:659 
Expires 06/2012 
Sophartex 
28500 
Vernouillet 
France 
White Tablet 
in transparent 
blister 
Good spectrum 
very similar to 
Erythromycin 
spectrum) 
No comparator 
to confirm 
Erythromycin 
Stearate tablets BP 
500mg,Batch: 227,  
Expires. 6/12 
Strides Red Tablets, 
coated 
Good spectrum  Confirm with 
Erythromycin 
stearate in 
laboratory 
Amodex® 500mg 
Batch: 186,  
Expires Nov 2012 
Synthelabo Capsule 
beige/ brown 
Good spectrum No Amoxicillin 
comparator 
available 
Chloramphenicol 
250mg, Batch165, 
Expires  Oct.2011 
Bailly-Creat Capsule white Good spectrum Confirm with 
Chloramphenicol 
In laboratory 
Chloramphenicol 
Capsules 250mg 
M&G Pharm. Capsule white Good spectrum Confirm with 
Chloramphenicol 
In laboratory 
Piroxicam Tablets 
20mg,Batch: 090601, 
Expires :04.06.12 
SPGC Sine 
Pharma 
Light yellow 
tablets 
Good spectrum Confirm with 
Piroxicam 
originator 
Ciprofloxacine 
500mg,Batch 
illegible 
 Expires 03/2012 
Strides 
Arcolab 
Bangalore 
India 
White tablets 
in transparent 
blister 
Good spectrum No 
Ciprofloxacin 
comparator in 
laboratory 
 METHODS AND MATERIALS 
 
64 
Product, Batch/ 
Expiration date. 
Manufacturer Appearance, 
Packaging 
Spectrum Identity test 
DOXIN
®
 
Doxycycline 100mg 
Yangzhou No 
3 
Pharmaceutic
al Ltd 
Jiangsu China 
Capsules 
green 
Fluorescence, 
but  peaks 
observed with  
Raman 
different crystal 
structure 
Doxycycline Capsule 
100mg, 
Batch:1350018 
Expired Jan.10 
LETAP 
Pharmaceutic
als. 
Accra. Ghana. 
Capsules 
green 
Fluorescence different crystal 
structure 
Doxycycline HCl 
100mg,Batch 7365,   
June2010 
Pharmaquick 
Cotonou -
Benin 
Yellow tablets Fluorescence different crystal 
structure 
Doxycap® 
Doxycycline 100mg, 
 Batch: AK0256 
Expires:8FEB.2010 
Hovid  
Accra-Ghana 
Capsule 
pink/green 
Fluorescence, 
but Raman 
peaks 
Doxycycline 
hyclate 
Erythrofil® 
(Erythromycin stearate) 
250mg.Batch S0754 
Expires :May 2010 
Fourrts 
(India) 
603 103 
Tamil Nadu 
Pink tablets Good spectrum Erythromycin 
stearate  
Ampicillin-3H2O 
250mg,  
Batch : illegible 
Expires:Nov.11 
LETAP 
Aaccra- 
Ghana 
Capsule 
red/black 
Good spectrum different crystal 
structure from 
the comparator 
Maloxine® 
(Sulphadoxine 
500mg + 
Pyrimethamine 
25mg), Batch: EM-
396, Expires 03/ 2011 
Shreechem 
Lab. 
White tablets 
(in non-
transparent 
packaging) 
Good spectrum Sulfacetamide 
(Sulphadoxine 
comparator not 
available 
Metronidazole Tabl. 
0.2g, Batch: 081008 
Expires:2011/10/30 
SINE White tablet Good spectrum Confirm with 
Metronidazole in 
laboratory 
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5.3.3. High-Performance Liquid Chromatography (HPLC) 
Chemical 
The following chemicals and reagents were kindly provided by the Institute of Pharmacy and 
Food Chemistry in Wurzburg; as reference, 
Ciprofloxacin AL 500 mg (AliudPharma), 
Doxycycline  Stada TABS 100mg and 
Amoxicillin pure substance used for educational purpose (experiments. titration). 
Acetonitrile, Triethylamine, Phosphoric acid, Potassium dihydrogenphosphate Sodium 
hydroxide were bought from FLUKA and were all of analytical grade, Millipore-water. 
 
Table5. HPLC Components for Ciprofloxacin and Doxycycline 
 
 Ciprofloxacin      Doxycycline 
Column 
reverse phase ODS C18 column 
250 mm × 4 mm (Phenomenex 
MAX-RP) 
reverse phase ODS C18 (2)  
column 250 mm × 4,6 mm,  
5 µm particle size 
Column temperature ambient temperature (25°C)          ambient temperature (25°C) 
Detector 
UV diode array detector  
wavelength: 278 nm 
         350 nm 
Injection volume 50.0 µL.          10 µL 
Mobile phase 
2,45 g o-phosphoric acid were 
dissolved in 1000,0 ml 
Millipore-water and adjusted to 
pH=3.0 with Triethylamine 
         Millipore water, acetonitrile  
          and perchloricic acid were mixed        
         (74:26:0.25) and pH was adjusted 
          to 2.5 with 5 M NaOH 
Flow rate 1.5mL min-
1
          1.0 mL min-
1
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We analyzed tablets, capsules, containing either ciprofloxacin, Doxycycline, Amoxicillin. In 
absence of Ciprofloxacin CRS (Chemical Reference Substance), Doxycycline hyclate CRS, we 
used: Ciprofloxacin AL 500 mg (Aliud Pharma); Doxycycline STADA TABS 100 mg. 
The content of active ingredients and excipients was determined quantitatively using validated 
HPLC-UV methods. All analyses were done according to European pharmacopoeia 
requirements. 
5.3.3.1.  Ciprofloxacin 
The liquid chromatography system used in the present study consisted of an Agilent Series 1200 
liquid chromatography equipped with a quaternary pump, a column thermostat (set to 25 °C), an 
automatic injector, an UV-VIS detector (set wavelength: 278 nm) and a degasser. A reverse 
phase ODS C18 column 150 mm × 4 mm, 4.6 mm diameter (Phenomenex HydroRP) was used 
and maintained at ambient temperature. The used standard was: Ciprofloxacin AL 500 mg 
(AliudPharma). 
Tested ciprofloxacin samples in the following table:  
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Table 6: Tested ciprofloxacin samples 
 
Brand Name 
Active 
ingredient 
Strength/Dosage 
form 
Procurement 
site 
X1 
Ciprofloxacin 
Strides 
Ciprofloxacin 500 mg / tablet Burkina Faso 
X2 Cipromax fort
®
 Ciprofloxacin 500 mg / tablet 
Assiganme 
Market Togo 
X3 Cipromax 500
®
 Ciprofloxacin 500 mg / tablet  
X4 Cipromax 500
®
 Ciprofloxacin 500 mg / tablet 
Phyto Riker Accra 
Ghana 
X5 Shalcip 500
®
 Ciprofloxacin 500 mg / tablet Accra Ghana 
X6 Ciproxamed 500
®
 Ciprofloxacin 500 mg / tablet Lomé-Togo 
X7 Cipromed 500
®
 Ciprofloxacin 500 mg / tablet 
Adjame -Abidjan 
Cote d´ivoire 
X8 Ciprobiotic forte® Ciprofloxacin 500 mg / tablet 
Assiganme 
Market Togo 
X9 Ciprofloxacin AL Ciprofloxacin 500 mg / tablet Germany 
 
The mobile phase was prepared as follows: 
2.45 g o-phosphoric acid were dissolved in 1000, 0 ml Millipore-water and adjusted to pH=3.0 
with Triethylamine. The elution was isocratic with 83 percent aqueous phase and 13 percent of 
acetonitrile. A flow rate of 1.5mL min-1 was maintained. Injection volume was set to 10 µL for 
the assay method and 50 µL for the impurities method. 
Calibration standards were prepared as follows: 
For linearity and calibration, five samples of Ciprofloxacin CRS were weighed into 100.0 ml 
flasks and brought to volume with mobile phase to obtain concentrations of 0.06, 0.25, 0.37, 
0.50, 0.62 mg/ml). The solutions were sonicated to obtain maximum dissolution. Each sample 
was injected three times and average peak areas were calculated.  
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The calibration curve was set up plotting obtained peak areas vs. concentration of ciprofloxacin; 
R² was calculated at 0.9999 (Fig.5): 
 
 
Fig.5: Calibration Curves for   Ciprofloxacine, Amoxicilline Doxycycline,  
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Table7: Assay of ciprofloxacin, Doxycycline and Amoxicillin samples 
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X1 
Ciprofloxacin 
Strides 
ciprofloxacin 
97.02 
c
ip
ro
fl
o
x
a
c
in
 
X2 Cipromax fort ciprofloxacin 97.72 
X3 Cipromax 500 ciprofloxacin 100.42 
X4 Cipromax 500 ciprofloxacin 97.91 
X5 Shalcip 500 ciprofloxacin 97.34 
X6 Ciproxamed 500 ciprofloxacin 95.13 
X7 Cipromed 500 ciprofloxacin 97.33 
X8 Ciprobiotic forte ciprofloxacin 99.22 
X9 Ciprofloxacin AL ciprofloxacin 98.77 
X1 
TetracyclinSpruk
efield 
tetracyclin* 
98.32 
d
o
x
y
c
y
c
li
n
e
 
X2 Doxin doxycyclin 118.51 
X3 Rogodox doxycyclin 116.88 
X4 Doxynor doxycyclin 110.15 
X5 
DoxycyclinPhar
maquick 
doxycyclin 
98.54 
X6 
Doxycycline 
Capsules 
doxycyclin 
162.19 
X7 
Doxycycline 
Capsules 
doxycyclin 
112.40 
X8 Doxycap doxycyclin 116.70 
X9 
Doxycycline HCl 
100 mg 
doxycyclin 
103.84 
X10 
Doxycyclin 
STADA 
doxycyclin 
106.32 
X1 
RGI Amoxicillin 
500 
amoxicillin 
102.50 
amoxicillin X2 Letap Amoxicillin amoxicillin 125.69 
X3 
KAV Amoxicillin 
BP 
amoxicillin 
** 
* calibration curve of doxycycline was used 
** sample was not able to be dissolved in the mobile phase 
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Samples for assay were prepared as follows: 
10 tablets were weighed; crushed and approximately. 100 mg were transferred into a 100 ml 
flask and dissolved in the mobile phase. The solutions were sonicated for about 30 minutes to 
obtain maximum dissolution. Afterwards, each sample was filtered into a vial using a 22 µm 
sterile filter. Each sample was injected three times and average peak areas were calculated. 
Assay:  Contents of unit doses were calculated using the regression plot and the average weights 
of one tablet: 
  ml 100 in sample dissolved
 w eightaverage
411.48
105.15-area peak average
 (mg) content
 
Impurities 
Determination of impurities was carried out under the same conditions as assay, also using the 
same sample solutions. The injection volume was set to 50.0 µL. Signals were detected at 278, 
272 and 254 nm compared via normalization of retention times. According to Ph. Eur. 6.0, the 
following impurities for ciprofloxacin are specified:  
 Fluoroquinolonicacid 
(7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4- dihydroquinoline-3-carboxylic acid 
 Ethylenediamine compound: 
7-[(2-aminoethyl)amino]-1- cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3- carboxylic 
acid 
 Desfluoro compound: 1-cyclopropyl-4-oxo-7-(piperazin-1- yl)-1,4-dihydroquinoline-3-
carboxylic acid 
 Decarboxylated compound: 1-cyclopropyl-6-fluoro-7-(piperazin-1- yl)quinolin-4(1H)-one 
 1-cyclopropyl-6-hydroxy-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 
 7-chloro-1-cyclopropyl-4-oxo-6-(piperazin-1-yl)-1,4- dihydroquinoline-3-carboxylic acid . 
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 The exact identification of the specified impurities in the samples was not possible due to a 
lack of CRS reference substances. 
 By normalization of obtained retention times according to Aksoy et al.
*
, identification of 
impurities B (Desfluoro compound), C (Ethylenediamine compound), D (7-chloro-1-
cyclopropyl-4-oxo-6-(piperazin-1-yl)-1,4- dihydroquinoline-3-carboxylic acid), 
E (Decarboxylated compound) and chloro– analogue was estimated (see table 9). 
 
Table 8: Normalization of retention times (Rt) in ciprofloxacin samples for peak identification 
X1 X2 
Rt 
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1.366 0.0216 0.212 solvent? 0.936 0.0587 0.146 solvent? 
2.921 0.076 0.454 Impur E 1.345 0.0613 0.210   
4.606 0.1174 0.715 Impur C 2.942 0.067 0.459 Impur E 
      4.615 0.2788 0.720 Impur C 
      5.642 0.1233 0.880   
6.438 99.785 1.000 Cipro 6.411 99.002 1.000 Cipro 
      7.98 0.3471 1.245 Impur D  
      14.184 0.0614 2.212 Chloro-a. 
X3 X4 
0.943 0.0356 0.147 solvent? 0.941 0.0472 0.148 solvent? 
1.339 0.0174 0.209  1.377 0.0458 0.217   
2.933 0.0658 0.458 Impur E 2.889 0.0743 0.454 Impur E 
3.428 0.0295 0.536  4.577 0.2956 0.720 Impur C 
4.634 0.1696 0.724 Impur C 5.594 0.0858 0.880   
6.398 99.6288 1.000 Cipro 6.359 99.141 1.000 Cipro 
14.183 0.0532 2.217 Chloro-a. 10.887 0.2456 1.712  
       14.047 0.0643 2.209 
Chloro-a. 
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X5 X6 
1.369 0.0152 0.214 solvent? 2.934 0.0934 0.455 solvent? 
2.935 0.0770 0.459   3.422 0.0369 0.530   
3.43 0.0363 0.537   4.613 0.1367 0.715 Impur C 
4.622 0.0650 0.724 Impur C 6.455 99.733 1.000 Cipro 
6.388 99.7540 1.000 Cipro        
14.073 0.0525 2.203 Chloro-a.        
X7 X8 
1.37 0.0878 0.211 solvent ? 0.943 0.0398 0.147 solvent? 
2.925 0.0632 0.450   1.066 0.0252 0.166   
4.614 0.2479 0.710 Impur C 1.525 0.0396 0.238   
6.495 99.1558 1.000 Cipro 2.942 0.1025 0.459   
8.034 0.4453 1.237 Impur D  3.442 0.0698 0.537   
    4.642 0.1847 0.724 Impur C 
       5.681 0.1415 0.886   
       6.411 99.304 1.000 Cipro 
    14.353 0.0928 2.239   
X9  
1.081 0.0168 0.164 solvent?     
2.994 0.0327 0.455       
4.738 0.0873 0.720 Impur C     
6.578 99.8632 1.000 Cipro     
  
* Aksoy B, Kücükgüzel I, Rollas S (2007) Chromatographia 66:S57-S63 
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Table 9: Ciprofloxacin - normalization of retention times after Aksoy et al 
Compound Rt RtCipro Quotient 
Ciprofloxacin 7.546 7.546 1.000 
Impurity E 2.797 7.546 0.371 
Impurity B 4.872 7.546 0.646 
Impurity C 5.517 7.546 0.731 
Impurity D 9.69 7.546 1.284 
Chloro-a. 15.591 7.546 2.066 
 
5.3.3.2. Doxycycline 
The liquid chromatography system used for the determination of Doxycycline was the same as 
the one used for determination of ciprofloxacin. (Table7) 
A reverse phase ODS C18 (2) column 250 mm × 4,6 mm, 5 µm particle size (Phenomenex Luna 
5u) was used and maintained at ambient temperature (25° C). For UV-VIS detection, the 
wavelength was set to 350 nm. 
The mobile phase was prepared as follows: 
Millipore water, Acetonitrile and Perchloric acid were mixed (74:26:0.25) and pH was adjusted 
to 2.5 with 5 M NaOH. The chromatography was carried out under isocratic conditions with a 
flow rate of 1.0 mL min-
1
. Injection volume was set to 10 µL for the assay method and 50 µL for 
the impurities method. 
Calibration standards were prepared as follows: 
For linearity and calibration, a stock solution of Doxycycline hyclate CRS was prepared (70.28 
µg/ml) and diluted with the mobile phase to obtain final concentrations of 14.06, 28.11, 42.17, 
56.22 and 70.28 µg/ml). Each sample was injected three times and average peak areas were 
calculated. The calibration curve was set up plotting obtained peak areas vs. concentration of 
ciprofloxacin; R² was calculated at 0.9904 (Fig 5).  
Samples for assay were prepared as follows: 
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10 tablets were weighed; crushed and approximately. 100 mg were transferred into a 100.0 ml 
flask and dissolved in the mobile phase. The solutions were sonicated for about 30 minutes to 
obtain maximum dissolution. Afterwards, each sample was filtered into a vial using a 22 µm 
sterile filter. Each sample was injected three times and average peak areas were calculated. 
Impurities 
Determination of impurities was carried out under the same conditions as assay, also using the 
same sample solutions. The injection volume was set to 50.0 µL. Signals also were detected at 
350 nm compared via normalization of retention times.  
Doxycycline: According to Ph. Eur. 6.0, the following impurities are specified:  
 6-epidoxycycline((4S,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5,10,12,2a-
pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-
carboxamide), 
 Metacycline((4S,4aR,5S,5aR,12aS)-4-(dimethylamino)-3,5,10,12,12a- pentahydroxy-6-
methylene-1,11-dioxo-1,4,4a,5,5a,6,11,12a- octahydrotetracene-2-carboxamide), 
 4-epidoxycycline((4R,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-
pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-
carboxamide) 
 4-epi-6-epidoxycycline(4R,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5, 10,12,12a-
pentahydroxy-6-methyl-1,11-dioxo-1,4,4a, 5,5a,6,11,12a-octahydrotetracene-2-
carboxamide. 
 Oxytetracycline 2-acetyl-2-decarbamoyldoxycycline ((4S,4aR,5S,5aR,6R,12aS)-2-acetyl-
4-(dimethylamino)- 3,5,10,12,12a-pentahydroxy-6-methyl-4a,5a,6,12a-
tetrahydrotetracene-1,11(4H,5H)-dione). 
Chromatograms of all samples showed a variety of additional peaks. As only reference retention 
times for Metacycline and 6-epidoxycycline were available, these two impurities probably can be 
identified at retention times of approximately 24.2 and 25.0 minutes ( Graphic 1: Chromatogram 
below)Tetracycline and Metacycline were present in all samples, whereas 6-epidoxycycline 
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seemed only to appear in samples X4, X5 and X9. (Table7) percental peak areas of Doxycycline 
varied between 85.1 to 97.4 per cent 
 
 
 
 
5.3.3.3. Amoxicillin 
The liquid chromatography system used for amoxicillin was the same as the one used before. 
Table.10: HPLC components for Amoxicillin 
     Amoxicilin Amoxicilline 
Column   
ODS C18 (2) column 
250 mm × 4,6 mm, 5 
µm particle size  
Column 
temperature 
  
35 °C 
Detector   274nm 
Injection 
volume 
  
25 µL 
Mobile phase   
Phase A- 0.2 M 
potassium phosphate 
buffer pH 7.0 - 
Millipore water 
(5:5:90 v/v) 
Phase B: Methanol - 
0.2 M potassium 
phosphate buffer pH 
7.0 - Millipore water 
(50:5:45 v/v 
Flow rate   1.0 mL min-
1
 
    
 
Figure 6: Typical chromatogram obtained with doxycycline samples 
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The column used also was ODS C18 (2) column 250 mm × 4,6 mm, 5 µm particle size 
(Phenomenex Luna 5u) operated at 35 °C.UV-VIS detection was carried out at 274 nm. 
 
The mobile phase was prepared as follows: 
Mobile phase A: Methanol - 0.2 M potassium phosphate buffer pH 7.0 - Millipore water (5:5:90 
v/v). 
Mobile phase B: Methanol - 0.2 M potassium phosphate buffer pH 7.0 - Millipore water (50:5:45 
v/v). 
A gradient elution was applied, with 5 % of mobile phase B for 5 minutes, then increasing at a 
rate of 2 % (B) to 65 % of B. Afterwards, decreasing at a rate of 8 % B to the original 
concentration. 
A flow rate of 1.0 mL min-1 was maintained. Injection volume was set to 25 µL for the assay 
method and 50 µL for the impurities method. 
 
Calibration standards were prepared as follows: 
For linearity and calibration, seven stock solutions of amoxicillin trihydrate CRS in mobile phase 
A were prepared to obtain final concentrations of 0.25, 0.33, 0.40, 0.48, 0.66, 0.70 and 0.90 
mg/ml). Each sample was injected three times and average peak areas were calculated. The 
calibration curve was set up plotting obtained peak areas vs. concentration of ciprofloxacin; R² 
was calculated at 0.9991 (Fig5). 
Samples for assay were prepared as follows: 
The content of 10 capsules was weighed; homogenized and approximately. 70 mg were 
transferred into a 100.0 ml flask and dissolved in the mobile phase A. The solutions were 
sonicated for about 15 minutes to obtain maximum dissolution. Afterwards, each sample was 
filtered into a vial using a 22 µm sterile filter. Each sample was injected three times and average 
peak areas were calculated. 
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Impurities:  
Determination of impurities was carried out under the same conditions as assay, also using the 
same sample solutions. The injection volume was set to 50.0µL. Signals also were detected at 
274 nm compared via normalization of retention times. 
Amoxicillin  
 According to Ph. Eur. 6.0, the following impurities are specified: 
 6-aminopenicillanic acid: 
(2S,5R,6R)-6-amino-3,3-dimethyl-7-oxo-4-thia- 1-azabicyclo[3.2.0]heptane-2-carboxylic 
acid. 
 L-amoxicillin: 
(2S,5R,6R)-6-[[(2S)-2-amino-2-(4-hydroxyphenyl)- acetyl]amino]-3,3-dimethyl-7-oxo-4-
thia-1-azabicyclo-[3.2.0]heptane-2-carboxylic acid. 
 Amoxicillindiketopiperazines: 
(4S)-2-[5-(4-hydroxyphenyl)-3,6-dioxopiperazin-2-yl]-5, 5-dimethylthiazolidine-4-
carboxylic acid. 
 Penicilloic acids of amoxicillin: 
(4S)-2-[[[(2R)-2-amino-2-(4-hydroxyphenyl)- acetyl]amino]carboxymethyl]-5,5-
dimethylthiazolidine-4-carboxylic acid. 
 Penilloic acids of amoxicillin: 
(2RS,4S)-2-[[[(2R)-2-amino-2-(4-hydroxy- phenyl)acetyl]amino]methyl]-5,5-
dimethylthiazolidine- 4-carboxylic acid-3-(4-hydroxyphenyl)pyrazin-2-ol 
 D-(4-hydroxyphenyl)- glycylamoxicillin: 
(2S,5R,6R)-6-[[(2R)-2-[[(2R)-2-amino-2-(4-hydroxy- phenyl)acetyl]amino]-2-(4-
hydroxyphenyl)acetyl]-amino]- 3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]-heptane-
2- carboxylic acid.  
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 (2R)-2-[(2,2-dimethylpropanoyl)amino]-2-(4- hydroxyphenyl)acetic acid (2R)-2-amino-
2-(4-hydroxyphenyl)acetic acid. 
 co-oligomers of amoxicillin and of penicilloic acids of amoxicillin oligomers of 
penicilloic acids of amoxicillin. 
 6-APA amoxicillin amide: 
(2S,5R,6R)-6-[[(2S,5R,6R)-6-[[(2R)-2-amino-2-(4- hydroxyphenyl)acetyl]amino]-3,3-
dimethyl-7-oxo-4-thia-1- azabicyclo[3.2.0]heptane-2-carbonyl]amino]-3,3-dimethyl- 7-
oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid. 
 
 
5.4. Findings 
All products tested passed the tests for identification of active ingredients indicating that the 
worst case of counterfeiting involving wrong active ingredients was not found. 
Ciprofloxacin samples complied with the specifications for assay in the European 
Pharmacopoeia. Labeled active ingredients were identified in all samples, however with varying 
dosages. Six of the nine (X2,X3,X4, X6, X7,X8 in table 7) Doxycycline samples analysed did not 
comply with the pharmacopoeial  requirements of 95–105%: 
Impurity determination was tried to be carried out via normalization of retention times of 
obtained chromatograms (see table 2), but conclusive allocation was not always possible.  
Impurities D and E (decarboxylated analogon) has been most likely present in all revised 
samples, but regarding other impurities, distinctive determination was not possible, though they 
also are present in every sample.  
When scoping the percentages of areas of these peaks, it is clear that, although impurities may be 
present, they aggregate to a very small rate.  
Unknown peaks, especially in Doxycycline measurement, may stem from beginning degradation 
of the active ingredient (epimerization, dehydratation, inactivation by means of reactions due to 
used excipients). As a non-pharmacopoeial method (Skulason, Ingolfsson: “Development of a 
simple HPLC method for separation of Doxycycline and its degradation products” Journal. 
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Pharm. and Biomed. Analytics, 33(2003) 667-672) was used for analysis, the results also have to 
be regarded with reserve. 
Differences in the amount of active ingredients may also result from bad manufacturing habits 
(inaccurate weighing or filling of capsules) or bad storage conditions, either from the side of the 
manufacturer or during the way to the laboratory. 
For Amoxicillin, no reference retention times with these chromatographic conditions were 
available at all. Sample X1 and X2 show similar peak patterns, especially at 3.1, 4.7, 5.2, 21.1, 
23.4, 25.2 and 27.1 minutes retention times. Percentage of the amoxicillin peaks were from 91.1 
to 91.2 per cent. (Chromatogram below) 
 
Figure 7: Chromatogram of Amoxicillin sample. 
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PART 4: RESULTS 
CHAPTER VI: Summary of Quality Failures 
Although the sample size in this study was small, it provides an indication about the availability 
of counterfeit /substandard antibiotics in Africa. Poor-quality medicines particularly affect 
lower-income countries, where inadequate infrastructure, non-regulated drug outlets and black 
market operations make drug quality surveys difficult. Drug regulation and information 
enforcement are scant. Patients may buy all types (OTC and Prescription Only Medicines) 
without consulting physicians. Taking in consideration 17 medicine sellers visited, in common 
practice, Patent Medicine Vendors (PMV) in Nigeria or Licensed Chemical Shops (LCS) in 
Ghana behaviors are:  
69% selling the requested medicine,  
30% giving their own suggestions to the customer, 
 19% asking questions about the illness, and 
21% providing instructions on how to take the medicine. 
Thus the major role of the LCS or PMV appeared to be just one of salesperson. Rarely, medicine 
sellers ask customers about their illness. Sellers with many years of experience do not sell 
immediately. They look at the customer’s attitude, the way he asks about the medicine in order 
to be sure that the customer is not from a regulatory body. Thus, according to the sort and 
quantity you want to buy, either you get it directly from the counter or you should wait until 
he/she brings it from the storage room which – usually – is up to five hundred meters away from 
the point of sales. For the security of their transaction, illicit vendors do not allow all their 
customers to know where they store their goods. In the case the seller is sure his/her customer 
may not be a trouble maker (not from regulatory authority) he/she takes the customer to the 
storage point. Fortunately, I had a chance to be taken to such a storage room. It was wonderful. 
The room was full of not only medicines (solid and liquid forms) from India, China and 
Singapore, but also of many sorts of medical devices and medicinal products manufactured or 
distributed by locally authorized manufacturers and distributors. There was no air condition to 
keep the temperature acceptable (ambient). I encountered this type of procurement places in 
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Lagos (Muhsin, Surelere, Agege), in Abidjan (Adjame Rossi), Lomé (Assiganme) and Cotonou 
(Dan Tokpa). There, you could see even medicines from Western countries. 
In official pharmacies in the respective survey countries, the service seems to be the same. 
Antibiotics are sold as OTC (over the counter) drugs in a single blister without package leaflet or 
in a small nylon bag according to the patient financial input. Physician’s prescription is not a 
must. “Most antibiotics are in the national Essential List*, that is why antibiotics are sold free of 
prescription,” said an employee in one pharmacy, but regulatory authorities in Ouagadougou 
(Burkina Faso) deny this statement. In a regular pharmacy in Ouagadougou (Burkina Faso), an 
employee receives the prescription (if any), brings the prescribed or requested medicine to the 
desk. Mostly, the one who takes the medicine from shelves is not the one who hands over 
medicine to the customer at the POS (Point of Sale); at the point of sale, it is generally a close 
relative of the pharmacist without any pharmaceutical training background, serving just as 
cashier. In all pharmacies I visited, the procurement of medicine in single blister form or retailed 
tablets and capsules enclosed in small plastic bags was more frequent although there were no 
instructions about side effects or any warning on storage to the patient. No matter if the patient is 
old, too young or illiterate. All of these practices permit the itinerant hawkers and illicit sellers to 
say that the only difference between their service and registered pharmacies is the price and since 
they are cheaper, the patients prefer to come to them. Most of the illicit sellers ignore that under 
high heat and humidity the medicines they are selling are degraded, some rely only on the 
expiration date printed on blister to ensure the quality to the consumer. 
 These Primary Medicine Vendor or Licensed Chemical shop roles can be enhanced through 
education, training and policy changes to standardize and legitimize LCS, PMV contributions to 
primary health care. This has been done in Ghana. The Ghanaian Pharmacy Act 489 from 1994 
permits the Pharmacy Council to license individuals as chemical sellers but does not specify any 
educational level as a requirement for licensure. However, the Pharmacy Council has set  
 
________________________ 
*  Essential List: The WHO has settled a list of ‘’drugs that satisfy the health care needs of the majority of 
the population; they should therefore be available at all times in adequate amounts and in appropriate 
dosage forms, at a price the community can afford." 
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the O-Level (Ordinary Level: a senior secondary school certificate or high school certificate) as 
the minimum qualification
*
. Despite this standard, some licensed chemical sellers are complete 
illiterates. The appearance of Licensed Chemical Shops and pharmacies is much alike. Some 
Licensed Chemical Shops even look more attractive than pharmacies. The difference between an 
LCS and a pharmacy is the description (writing) in front of the building. For Licensed Chemical 
Store   the law does not specify the educational level of the seller/distributor. In pharmacies you 
may find a graduated pharmacist. In Ghanaian law, pharmacies are permitted to dispense or sell 
all kinds of medicines whereas licensed chemical stores are authorized to sell only OTC (Over 
the Counter) drugs.Selling medicine is a business with tentacles in all corners of Africa where 
people perceive a need to buy medicinal products. In this context, the PMV can be broadly 
defined as a person without formal pharmacy training who sells orthodox pharmaceutical 
products on a retail basis for profit. 
Price differentials create an incentive for drug diversion within and between established 
channels. There is a lack of effective intellectual property protection and due regard is not paid to 
quality assurance. Parallel trade in pharmaceuticals generates a number of monitoring difficulties 
that are less apparent but significant threats to safety. With drugs entering through porous 
borders, safety warnings and product recalls are more difficult to execute. In addition, product-
packaging standards vary across markets and prescription recommendations as well as 
contraindications also may differ. Differences in product packages remove the familiar 
packaging clues that are important in the visual detection of counterfeits. Parallel trade results in 
unregulated distribution pipelines and weakened regulatory control of the supply chain, both of 
which are characteristics that facilitate counterfeiting. 
The local industry desperately needs support via capacity building in order to enable them to 
meet the required quality standards. The quality testing study outcomes suggest the need to 
enhance the quality of medicines on the market. 
 
 
 
 
_________________________ 
* Training and Accreditation standards. Available from www.pharmacycouncilghana.org;accessed on 
February 23
rd
 2010  
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PART 5:  DISCUSSION, CONLUSION AND RECOMMENDATIONS 
CHAPITER VII: Discussion 
We acknowledge that a broad review of quality assurance of medicines over an expansive and 
complicated area such as Africa is a challenge. As it appears from our review, there is few data 
on which to judge drug quality, as few objective studies have been conducted in Sub-Saharan 
Africa. A clear distinction needs to be made between counterfeit and substandard products. 
There is tendency in the literature to use the two terms interchangeably as highlighted by 
Shakooret al
78. The WHO defines counterfeit products as “...those deliberately and fraudulently 
mislabeled with regard to identity and/or source...”79 Whilst it is the case that most counterfeit 
products are sub-standard, there are some that are within the specified pharmacopoeial limits as 
shown by Atemnkeng et al in the DR Congo 
80
.The review showed that in Africa most products 
are sub-standard and not counterfeit
81
, pointing perhaps to lack of enforcement of Good 
Manufacturing Practices (GMP) rather than a deliberate attempt to defraud. Drug action is such 
that a minimum concentration is required to elicit a physiological response (lowering of elevated 
blood glucose levels in diabetes mellitus for instance) or killing parasites in the case of infectious 
diseases .Sulfadoxine and Pyrimethamine tablets exhibit notoriously poor in-vitro dissolution 
profiles, especially with regard to the Pyrimethamine component. This is mostly a problem with 
the generic products rather the originator. It is thought that this is due to the poor aqueous 
solubility of Pyrimethamine occasioned by the use of poor quality raw materials or poor choice 
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of excipients in the formulation.
82,83
. The pharmacopoeia assumes a good in vitro-in vivo 
correlation such that a product which failed in vitro dissolution will most likely fail in an in vivo 
(bioavailability) test and therefore result in a low plasma level of Sulfadoxine and 
Pyrimethamine with the attendant risks of therapeutic failure. The few studies done here are 
inconclusive as they have been faulted on sample size requirements due to restricted budget. 
However, in the case of the Artemisinins, which are used as first-line therapeutics in at least 30 
Sub-Saharan countries
84
, the incidence of counterfeit Antimalarial drugs is increasing. The basis 
for this assumption is that these high value products are consumed by millions of Africans each 
year and therefore represent a profitable business opportunity. Ensuring the quality of medicinal 
products is important throughout the whole distribution chain, storage and dispensing outlets. A 
very good drug that leaves the factory gate might well be worthless a few months later due to 
rapid deterioration as a result of exposure to excessive moisture and temperature at the point of 
sale. This has serious implications for the ACTs which are the favored first-line Antimalarial for 
most of Sub Sahara Africa. The Artemisinins are hygroscopic and have a short shelf life of 36 
months or less. It is imperative to study how these drugs hold up under typical storage and 
handling conditions in the tropics as they probably constitute the latest effective drugs against 
the lethal Plasmodium falciparum malaria. 
What remains is how the ECOWAS ´States can collectively leverage economies of scale to the 
mutual benefit to address access and quality concerns. However, tighter enforcement of some 
regulations could have a negative on public health. Eliminating all prescription only medicines 
(POM) from drug stores could restrict the access of poor rural populations to effective 
medicines, particularly where government facilities or formal pharmacies are out of reach.  
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This would inevitably drastically reduce drug availability in rural areas. Enforcing the regulation 
that only drugs in unit packs should be sold over-the-counter has the potential to guard against 
tablet contamination and degradation, and to improve labeling and dosing instructions, which in 
turn has been demonstrated to improve treatment adherence (WHO 2004). However, this could 
substantially increase the cost of pharmaceutical products. For example packaged Sulfadoxine
 Pyrimethamine (SP) was on average 1.8 times the retail price of loose SP tablets (Goodman 
2004). Although packaged drugs may be perceived as better quality, such an increase in price 
would run the risk of further reducing the proportion of patients who purchase an adequate 
antibiotic dose.
 
CHAPTER VIII: Conclusion and Recommendations 
8.1. Conclusion 
Problems concerning drug safety and efficacy are generally caused by drugs containing toxic 
substances or impurities, substandard preparations or counterfeits. All of these problems can be 
tackled effectively only by establishing an effective drug regulatory system. It is very clear to all 
healthcare professionals that a major source of substandard products in Sub-Saharan Africa is the 
multitude of unregulated drug markets in major cities. These unregulated markets have existed 
since the 60’s in rural areas which have never been penetrated by official pharmacies and have 
grown in number and complexity over the years with globalization. Medicines peddlers and 
medicinal products on market stall have survived the efforts of various governments to forcefully 
dismantle them, which never succeeded, but rather ended up in life attempt against national 
health authorities.For a great proportion of the developing countries, health conditions are 
worsening, perspectives for improvement are not encouraging and without a fundamental change 
in the pharmaceutical market supported by a strong political will, the slogan “health for all” will 
not come to fruition in the near future. I could observe during my research survey that all West 
African countries are commonly facing the ravages of infectious diseases and nowadays 
cardiovascular diseases and diabetes. Adopting individualistic approaches in sourcing essential 
medicines, the countries lose the one leverage (influence) that could have been utilized through a 
pooling of regional resources. Shall ECOWAS countries use a data to select which drugs actually 
could address the largest proportion of diseases that commonly affect the region, subsequently 
all countries could engage themselves in the so called “pooled procurement” by which all 
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 West African states identify their medicine needs and identify the supplier that offers the best 
competitive pricing and quality terms. In this scenario stakeholders would no longer negotiate 
with separated, local health agencies such as Ghana Food and Drugs Board or Directorate for 
pharmacy, laboratory and medicine devices from Togo but with a single entity representing the 
whole of West Africa standing together. How to ensure that medicines entering in ECOWAS are 
of the required standards? The network should be based on an approach of shared responsibilities 
among the participating states; e.g. Ghanaian regulatory body: the Food and Drugs Board (FDB) 
and Cote d´Ivoire ´s DPLM (Direction des Pharmacies Laboratoires et du Médicament) may 
ensure a common harmonized pharmaceutical regulatory system to achieve international Good 
Manufacturing Practice standards, while Nigeria ´s NAFDAC takes care of post marketing 
surveillance. Hopefully this means that only drugs of a certain standard gain access to regional 
market and hence to patients. The economic burden of expensive drugs which may not be 
feasible for a single country might be addressed by a conglomerate of ECOWAS countries 
resolved to ensure access to quality drugs for their entire population. Could West African States 
thus consider a future of shared roles and responsibilities, where Liberia and Benin do post-
market surveillance for Antimalarials, Nigeria sorts it out for Antiretrovirals while the Gambia 
and Senegal do same for all Antituberculotic drugs on the West African market? The last area 
worthy of collaboration is that of building the human capacity of local pharmaceutical industries 
and quality control laboratories to meet prequalification standards. With such a commitment, 
there shouldn’t remain any obstacles which could prevent the West African States from 
manufacturing medicines of the highest quality in order to meet the regional collective needs. 
Drug regulatory authorities should foster regular communication with local manufacturers. They 
should also acknowledge the right of citizens to be provided with accurate and appropriate 
information on drugs marketed in their country. Educating citizens about the efficacy, safety, 
quality and rational use of drugs will ultimately enhance the achievement of regulatory 
objectives. 
A regional harmonized medicine regulatory authority promises the following advantages for the 
Pharmaceutical sector and public health in general: 
 One umbrella for all manufacturers, importers and distributors in each ECOWAS country. 
Local manufacturers will also gain immensely in the area of capacity building and utilization 
of countries networking.  
 The manufacturers and consumers will enjoy the economy of scale (which remains the only 
attraction to the illegal markets) in a sanitized, well-regulated and controlled environment.  
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 Full involvement of trained pharmacist at every point of ethical drug distribution combined with 
effective regulation, ensure the availability of quality and safety of pharmaceuticals for the 
consumer. 
 An environment easier to regulate and control.  
 The various regulatory Agencies will therefore enjoy more cooperation and the resultant 
synergy in their activities.  
 The sanitized system will make it impossible for criminals to find their way into drug trade 
channels, since there has to be a thorough screening before anyone is accepted into the 
regional market.  
 Combating health workforce shortages and poor work environments is critical, requiring the 
planning and implementation of comprehensive and integrated approaches without delay.   
Training, sustaining and retaining a motivated and supported workforce will require long-term 
commitment, structural and fiscal changes, and partnerships at country, regional and 
international levels. Developing effective policies and strategies for the retention of health 
personnel, such as the review of salaries and implementation of incentive schemes and the 
strengthening of human resources planning and management will enhance the workforce.  
 At international level, it’s necessary creating synergies through communication, collaboration 
and cooperation. Support regional harmonization initiatives by sharing experience from 
harmonization processes and providing expertise in support of harmonization. 
Support participation of regulatory staff in harmonization initiatives such as the African 
Medicine Regulation Harmonization Initiative (AMRHI)
85
. 
 Encourage the process of implementation good quality management system. With a long term 
vision, assurance of equivalent approach to manufacture and control of medicines, authorization 
and supervision of clinical trials, as well as frequent controls in procurement and retail outlets. 
Focus on where products are made and tested.  Provide opportunities for training of drug quality 
control laboratory staff to improve quality testing skills and support/partnering with local 
manufacturers to transfer appropriate technology, human, equipment and technical knowhow to 
produce quality essential medicines locally at reasonable costs. 
                                                 
 
85
“African Medicines Registration harmonization Initiative (AMRHI) summary status and future plan”. 
available on http://drop.io/AMRH_Internetaccessed on April 23rd,2011. 
DISCUSSION, CONLUSION AND RECOMMENDATIONS 
88 
 Adjust prices of medicines intended for low income countries-to local financing reality and 
apply specific labeling to prevent their re-entry into the Western market e.g. ARV 
(Antiretroviral) drugs  against Human Immunodeficiency Virus HIV. 
 Develop affordable appropriate technologies; suitable, reliable, and less time consuming 
analytical methods and tools for monitoring the quality of medicines in the market e.g. portable 
minilabs, Raman Truscan. Support establishment of regional Bioequivalence centers that will 
conduct studies at reduced cost for medicines manufactured locally. 
In order to sanitize the drug distribution channels, the permanent dismantling of illegal markets 
is of paramount importance. To this end the WAHO (West Africa Health Organization) proposed 
the concept of regional harmonized drug regulation and distribution
86
. For any pharmaceutical to 
satisfy the legal requirements of any ECOWAS country into which it is imported, consideration 
should be given to the pre documentation approval such that clearance is provided prior to arrival 
of any medical consignment . Whilst importation regulations vary from country to country, 
below are the regulations which NIGERIA provided as an example. 
(a) There must be evidence of registration of the product in the country of the manufacturer i.e. 
product license /Certificate of registration 
(b) There must be evidence by the competent health authority that the sale of the product does 
not constitute a contravention of the drug laws in the manufacturer´s country, e.g. Certificate of 
Pharmaceutical Product (COPP) that conforms to WHO format. 
(c)The documents in respect of (a) (b) shall be authenticated by Nigerian Mission in that 
exporting country. 
The whole objective is to create an ordered network for the regulation sale and distribution of 
wholesome pharmaceutical products under the supervision of one regional health institution. 
Entry of pharmaceuticals into the ECOWAS market will be controlled and restricted to drugs 
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that have satisfied all WAHO requirements for safety and efficacy. When the regional medicines 
regulatory bodies have been put in place and are being managed by duly authorized people, 
professionals will surely opt to patronize them. WAHO can then proceed to demobilize the 
existing unregulated open markets. This will diminish the current need for existing illegal 
markets and will make it easier for national health authorities and law enforcement agencies to 
close down such markets. In such circumstances, the social impact of the closures will be 
minimized and the chances of getting local governments involved in the exercise will be 
enhanced. A clear sense of duty on the part of employees is important if regulatory processes are 
to be pursued consistently. 
Regulatory processes should be systematically monitored in order to identify problems and 
determine whether the actual activities match the intended actions. Ensuring the safety, efficacy 
and quality of drugs available to the public is the main aim of drug regulation. If regulatory goals 
are to be achieved, appropriate structures must be established and appropriate activities carried 
out to achieve the desired goals. 
We believed that a similar study involving a bigger number of countries representing different 
levels of development would provide deeper insight into the strengths and weaknesses of drug 
regulatory authorities and the different strategies used to improve drug regulation performance. 
 
8.2. Recommendations for Effective Drug Regulation. 
Every regulatory action contributes to ensuring the safety quality and efficacy of drugs. A clear 
sense of the mission of the regulatory authority is important in motivating DRA staff to pursue 
regulatory processes in order to achieve drug regulation. This study found that there was a high 
prevalence of poor quality drugs. The findings provide areas for public intervention to improve 
the quality. The regulatory capacity of the whole ECOWAS region in the area of post market 
surveillance needs to be strengthened by training more field inspectors and boosting the testing 
capacity (equipment and logistics) of the Quality Control Laboratory.  
The collaboration between all pharmaceutical stakeholders, the WHO and their funding partners 
such as World Bank needs to be strengthened to improve national medicines quality assurance 
infrastructure in the interest of public health and safety. 
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 There should be enforced checks and regulation of drug supply management as well as stricter 
penalties for people stocking substandard and counterfeit drugs. Self-assessment can help an 
organization to learn about its own strengths and weaknesses. Transforming each Drug 
Regulatory Authority (DRA) into a learning organization which routinely conducts self-
assessment and continuous quality improvement can be a powerful approach to enhancing drug 
regulatory performance. Systematic evaluation allows an objective and comprehensive appraisal 
of performance and identification of strengths, weaknesses and measures for improvement. 
Regular evaluation enables a DRA to learn continually about the quality of its performance, and 
to develop awareness of any positive or negative changes in that performance. This involves 
setting up mechanisms for mutual review of drug regulation systems. It serves as a means of 
external auditing (peer review), whereby the performance of one agency can be compared with 
that of others. Comparing The NAFDAC and the Burkina Faso quality control laboratories with 
the Kenyan WHO prequalified MEDS (Mission for Essential Drugs Supply) quality control 
laboratory is an example. Proficiency tests are performed by the participating laboratories in 
such a way that each laboratory learns how well it is performing in comparison with the others
87
. 
To overcome human resources problems, coordination may be established between the DRA and 
the country's educational institutions, to provide the number and types of pharmaceutical 
competency which are needed. The aim is to develop skills through short training courses. A 
coherent, module-based educational package like the one initiated since autumn 2010 by the 
West Africa Health organization (WAHO) may be developed by collaboration between 
countries. Since drug regulation involves various stakeholders with commercial interests who 
may try to exert pressure on the authority in order to secure decisions in their favor, health 
authorities should employ people with the specialized knowledge and skills required to ensure 
effective drug regulation. Employees must be individuals of integrity and should be well 
remunerated. 
Health insurance through basic but strong mutuality and prescription drug coverage, will address 
an affordable health system. Manufacturer’s price dumping, this alternative would require 
                                                 
 
87
 Sauwakon Ratanawijitrasin, Eshetu Wondemagegnehu. “Effective drug regulation- A multicountry 
study”. A book published by World Health Organization 2002 WHO Library Cataloguing-in-Publication 
Data  ISBN 92 4 156206 4 . 
DISCUSSION, CONLUSION AND RECOMMENDATIONS 
91 
pharmaceutical manufacturers to change their pricing policies in existing low-price countries. 
Prices would increase to a uniform price level, but manufacturers would offer rebates that would 
be aid to the payer or national health system. Drugs consumed domestically in low-price 
countries would be subject to government price controls, while exported products would be 
priced according to market forces. It should be possible to institute this pricing policy through 
contractual agreements between manufacturers and suppliers. 
The essential drugs concept is evidence based, simple, promotes equity, and is firmly rooted in  
public health principles.This strategy is a proven success but it needs to be  strengthened, and 
new ways of implementation have to be explored, given the changing context.
REFERENCES  
92 
CHAPTER IX: References 
9.1. Annexes 
Annex1: Compilation of NAFDAC List of some identified fake products (From October 2001-December 2005) 
Identity of faked Item 
Difference(s) 
Genuine Fake type 
Ampiclox Capsules 500mg® 
By SmithKline Beecham 
Ampiclox® Capsules 500mg 
By SmithKline Beecham 
Contains labeled content of active 
ingredient. 
Registered by NAFDAC, Registration 
#04-0181 
.Amcilox 500 caps® Made in 
India by Dotsy 
Pharmaceuticals P.Ltd, Phase 
II.Extn .Nodia 201.301 
Very low content of active 
ingredient 
Ciprolex® 
Ciprofloxacin Tables USP 500mg 
Ciprolex®: Ciprofloxacin Tablets 
USP 500mg 
Manufactured for: London United 
Exports Ltd London NW4 England. 
By AGLOWMED Ltd.A1-6104/2 
GIDC INDIA 
There are holograms on both blister 
and protective foils. Registered by 
NAFDAC Registration # 04-2719 
 
CIPROLEX®: Ciprofloxacin 
Tablets USP 
500mg.Manufactured for 
LONDON UNITED 
PHARMACEUTICALS 
LONDON ENGLAND. 
No name and location address 
of manufacturer. 
There is no hologram on 
packet and the product does 
not have protective foils. 
Not registered by NAFDAC 
Sulfadoxine & Pyrimethamine 
Tablets 
Several registered brands 
MALARIGO® 
(Sulfadoxine &Pyrimethamine 
Tablets UST) 
 3tablets 
Exported by AMARDAHAN 
TRADERS & EXPORTERS 
PVT:LTD 
Sarigam 396 155,Dist.Valsad 
Not registered by NAFDAC 
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Doxycycline Capsules 
Vibramycin® Capsules: Doxycycline 
100mg 
Has only English wording on the 
package .Manufactuered by Pfizer 
Products,Plc 1 Henry Carr Street Ikeja 
– Lagos. 
NAFDAC Registration No. 04-0552 
1. DOXYCYCLINE 
CAPSULES  100mg. 
Has English and Arabic 
inscription on the pack. 
Manufactured by TABROS 
PHARMA; L 29/B Sector 22 
FB Industrial Area Karachi 
75950 Pakistan Not registered 
by NAFDAC. 
2. Monodox® 100mg 
10stuck 
 Merckle GmbH; Blaubeuren 
BDR. All wording on package 
and instruction leaflet in 
German language. Not 
registered by NAFDAC 
 
  Source: NAFDAC Bulletin 2001-2005. 
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Annex 2: Samples collected in Lagos, from 19
th
 to 22th January 2010 
Brand Name Active 
Substance/Strength 
Manufacturer/ 
Distributor 
Procurement 
Site/Date 
Concerns 
Cenox® Ciprofloxacin 
500mg 
Elbe Pharma 
Nigeria Ltd. 
Pharmacy and 
Stores Ltd. 
IyanaIpaja 
Lagos/Jan.21,2010 
Product with two 
different addresses. 
Registered by 
NAFDAC under 04 
3002 in the current 
register (first edition) 
Green Page with 
location in Plot 1 M/M 
Int'l Airport Isolo 
Lagos; but the outer 
package carries a 
different address: Elbe 
PharmaIkoyi, Lagos 
Chlomacol® Chloramphenicol 
BP.250mg 
Yangzou No.3 
Pharmaceutical.Co 
Jiangsu -China/ 
Distributed by 
Geneith 
Pharmaceuticals 
Kech Pharmacy & 
Stores Ltd. Ekoro 
Road AbuleEgba, 
Lagos/ 
 January 21.2010 
Chlomacol®. has 
NAFDAC 
Reg.No. 04-3729 . 
On the homepage of 
Geneith global Pharm, 
Chlomacol is registered 
under NAFDAC 
 Reg. No.04 3481. 
Labeling information is 
inadequate. The 
samples  
I bought in Kech 
Pharmacy Lagos with 
NAFDAC Reg.No. 04-
3429 have the 
following information 
on their package leaflet: 
Contraindication: 
“Children fewer than 8 
years or age should not 
be treated.” 
Dosage and 
administration:   
“Children in dose of 25 
to 50mg/kg 3-4 times 
daily.” 
Durban250® Choramphenicol 
250mg 
Greenfield 
Pharmaceutical 
Jiang Su PR China 
Lagos/  
January 19, 2010 
Inadequate labeling 
(readability); text not 
legible not clear and 
easy to read. 
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Brand Name Active 
Substance/Strength 
Manufacturer/ 
Distributor 
Procurement 
Site/Date 
Concerns 
Labcin500® Erythromycin 
500mg 
Embassy 
Pharmaceutical and 
Chemicals Ltd. 
Lagos 
Cool United 
Pharmaceutical 
Onimaya-Road 
Agege.Lagos  
The information on the 
package leaflet are not 
complete, incorrectly 
written and meaningless 
(Special Precautions, 
Pregnancy, Lactation, 
Eldery). The labeling 
“For Medical/Pharmacy 
Professional Only” is 
not written on the out-
package. 
Despite all, 
LABCIN500 is 
registered in 
NAFDAC's current 
fifteenth edition Green 
Page under NAFDAC 
Reg.No. 04-6174 
RGI 
Amoxicillin500® 
Amoxicillin 
500mg 
RichyGold 
International Ltd. 
Oshodi-Lagos 
Rome Park 
Enterprises, off 
Ojuwoye Market 
Mushin,Lagos/ 
January 22,2010 
Labeling not easy to 
understand 
(contraindication) 
CIPROVAM® 
500 
 
Ciprofloxacin 
500mg 
TuyilPharm.INDIA
.LIMITED 
 
ZomezConcern 
(NIG) Agaran 
Street, 
Mushin,Lagos 
January 22,2010 
Both outer package and 
labeling carry 22 New 
Yili-Road Ilorin 
Nigeria; but the address 
on the blister is: 22, 
Stadium Road Ilorin 
Kwara State Nigeria 
Erythr®500 Erythromycin 
500mg 
JiansuRuinianQianj
in Pharmaceutical 
Jiansu Province 
China/ 
VIXA 
Pharmaceutical Co. 
Ltd. Ogudu, Lagos 
Lagos The brand name on the 
blister is Erythr instead 
of Erythr500; 
NAFDAC Reg.No. is 
A4-2338, usually 04, 
not A4; and the 
Erythr500 is not 
registered in 
NAFDAC's current 
Green Page 
Lampicin® 
 
Ampicilin 250mg Me Cure Industries 
Ltd. Oshodi, Lagos 
Mushin Market 
date: 
January 22, 2010. 
 
Inadequate and unclear 
labeling of the leaflet. 
Self life: Two years 
from manufacturing 
date and one year from 
expiration date; dosage 
is written incorrectly 
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Brand Name Active 
Substance/Strength 
Manufacturer/ 
Distributor 
Procurement 
Site/Date 
Concerns 
Quintor®500 Ciprofloxacin 
500mg 
Torrent 
Pharmaceutical 
Ltd. 
Distr. Mehsana 
India 
Jan AbuleEgba 
Clinic, Lagos  
January 20, 2010 
Inadequate and unclear 
labeling of the leaflet. 
Self life: Two years 
from manufacturing 
date and one year from 
expiration date; dosage 
is written incorrectly 
Ucillin®250 Ampicillin 250mg Greenfield 
Pharmaceutical 
Jiang Su Co.Ltd 
India 
Ilupejo Lagos/ 
January 22,2010 
Both outer packaging 
and leaflet are 
addressed 15, Wilmer 
Street Off town 
planning way Ilupeju 
Lagos, but in the 
national register (Green 
Page),  
8, Ipaye Street, Aguda, 
Surulere Lagos 
 
 
Annex 3. Samples collected in Burkina Faso: January 30 to February 10, 2010 
Most medicines are sold in a single blister without packaging or information leaflet. I asked in a 
formal selling point (Yaldago Hospital Pharmacy) why such a practice, and I was told that 
patients are supposed to know what they are buying and that many of them are under treatment 
by a physician and were advised which medicines to buy. Here, the seller who is supposed to be 
a professional sold some antibiotics to me without prescription and showed me on a computer 
screen that Erythromycin, Amoxicillin and Ciprofloxacin are sold without physician's 
prescription. 
The following medicines have been collected in single blister form:  
 
Brand Name Active 
Substance/Strength 
Manufacturer/ 
Distributor 
Procurement 
Site/Date 
Concerns 
Amoxicillin 
500mg 
Amoxicillin 500mg Strides Arcolab 
Limited 
Bangalore-India 
Yaldago Hospital 
Pharmacy, 
Ouagadougou 
February 2, 2010 
Amoxicillin 500mg 
is sold in single 
blister form in 
 an ordinary 
pharmacy without 
user information 
leaflet 
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Brand Name Active 
Substance/Strength 
Manufacturer/ 
Distributor 
Procurement 
Site/Date 
Concerns 
Ampicillin 
500UBI 
Ampicillin 500mg Ubigen Pharmacy Diawara 
Ouaga 
February 10, 2010 
Amoxicillin 500mg 
is sold in single 
blister form in an 
ordinary pharmacy 
without user 
information leaflet. 
Erythromycin 
500mg 
Erythromycin 500mg Bristo-Myers 
Squibb. 
Yaldago Hospital 
Pharmacy, 
Ouagadougou 
February1, 2010. 
 
Single blister sold in 
ordinary pharmacy 
without package 
leaflet 
Ciprofloxacin 
250mg 
Ciprofloxacin 
Hydrochloride o,25g 
Chinese Drug 
Store Ets. Yan 
Yan Rue Patrice 
Lumumba 
Ets Yang Yang 
January31, 2010 
Sold in general store 
where all articles 
including food stuff 
,shoes are from 
China, labeled in 
Chinese language 
Ciprofloxacin 
500mg 
Ciprofloxacin 500mg Pharmacy de la 
poste BP.2829 
Ouagadougou 
Pharmacy de la poste 
BP.2829 
Ouagadougou 
February 6, 2010 
Ciprofloxacin sold in 
blister without 
Patient information 
leaflet. 
Metronidazole 
0,2g 
Metronidazole 0,2g Illegible(labeling 
in Chinese 
language) 
Ets. YangYang.          
Rue Patrice 
Lumumba 
January31, 2010 
labeled in Chinese 
language in a French 
speaking country. 
The store holder does 
not speak either local 
language or French. 
Maloxine Sulphadoxine USP 
500mg 
Pyrimethamine USP 
25mg 
Schreechem 
Laboratories 
Bombay 
400083.under 
licence from 
Exphar SA 
Belgium 
Ets. YangYang.          
Rue Patrice 
Lumumba 
January 31, 2010 
The forensic test with 
TruScan in Germany 
reveals suspicions of 
counterfeiting; 
probable substitution 
of sulphacetamide to 
sulphadoxin. On the 
package, it is 
mentioned 
“Exclusively for St. 
Michael 
Pharmaceutical Ltd 
Lagos Nigeria. 
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Brand Name Active 
Substance/Strength 
Manufacturer/ 
Distributor 
Procurement 
Site/Date 
Concerns 
Metronidazole 
0,2g 
Metronidazole 
200mg 
illegible (labeling 
in Chinese 
language) 
Ets.Yang Yang Rue 
Secteur1 zone 
commerciale 
Ouagadougou 
January 31, 2010 
The seller gave and 
could not write 
Metronidazole on the 
receipt. 
Piroxicam 
20mg 
Piroxicam 20mg Sine 
China 
Hawker on the 
Patrice Lumumba 
road 
The seller is illiterate 
and sells medicines 
labeled in Chinese 
language. 
 
 
Annex 4:  Samples collected in Ghana: February 19
th 
to February 28
th
, 2010  
Compare to other countries in the region, it is very rare to meet hawkers or peddlers along the 
roads in the cities. Substandard and illicit drug stores are localized in Agbogboloshi market, 
Nima market and Makola lorry station. Here, you may get your medicines only when you ask. 
Medicines are not exposed on market stalls. In drug stores and ordinary pharmacies medicines 
are sold even retailed in two capsules/tablets in small paper or nylon bags; according to your 
budget. No therapeutic plan is handed to patients. In many drugstores, vendors are illiterates or 
with very low education level. 
 
Brand Name Active Substance/ 
Strength 
Manufacturer/ 
Distributor 
Procurement 
Site/Date 
Concerns 
Amoxicillin 
500mg 
Amoxicillin 
500mg 
LetapPharmaceuticals 
Ltd 
Healthmatch 
Pharmacy.Samora 
Marchel road Accra 
February 26, 2010 
Medicines are sold 
without user 
information 
Ampicillin 250mg Ampicillin 250mg Ayrton Drug Ltd. 
Accra 
Licensed chemical 
Store Nima Accra 
Medicines are retailed 
in small nylon bag 
.No user information 
available 
Ampicillin Caps Ampicillin 500mg Letap Pharmaceuticals 
Ltd 
Maple Leaf 
chemistry/Accra 
February 25, 2010 
Medicines are retailed 
in small nylon bag 
.No user information 
available 
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Chloramphenicol 
Capsules 
Chloramphenicol 
250mg 
Ayrton Drugs Ltd. 
Accra 
Maple Leaf 
chemistry/ 
February 25, 2010 
Sold in blister form 
without without user 
information attached. 
Doxycycline 
Capsules 100mg 
Doxycycline 
100mg 
Letap Pharmaceutical 
Accra 
Ghana Postal Clinic  
February 25, 2010 
Sold in blister form 
without user 
information attached. 
Rocaf® Blister Chloramphenicol 
250mg 
Ernest Chemistry 
Accra 
Healthmatch 
Pharmacy.Samora 
Marchel road Accra 
February 26, 2010 
Sold in blister unit 
without user 
information attached 
 
 
Annex 5.  Samples collected in Benin: March 2
nd 
to March 6
th
, 2010. 
 
Brand Name Active Substance/ 
Strength 
Manufacturer/ 
Distributor 
Procurement 
Site/Date 
Concerns 
Ciplox 500® Ciprofloxacin USP 
500mg 
CIPLA LTD India Pharmacie des 4 
Thérapies, Cotonou 
No address from 
manufacturer/Distributor 
Ery500mg® 
Batch:647 
Erythromycin 
500mg 
Sophartex 
28500Vernouillet 
France 
Dantokpa Market, 
Cotonou. 
March 3, 2010 
Ery 500mg was bought 
to compare the quality 
of the same product 
purchased from open 
market and from formal 
air conditioned 
pharmacy 
Ery500mg® 
Batch:659 
Erythromycin 
500mg 
Sophartex 
28500Vernouillet 
France 
Dantokpa Market, 
Cotonou. 
March 3, 2010 
Ery 500mg was bought 
to compare the quality 
of the same product 
purchased from open 
market and from  air 
conditioned pharmacy 
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Brand Name Active Substance/ 
Strength 
Manufacturer/ 
Distributor 
Procurement 
Site/Date 
Concerns 
Ciplox 500® Ciprofloxacin USP 
500mg 
CIPLA LTD India Pharmacie des 4 
Thérapies, Cotonou 
No address from 
manufacturer/Distributor 
Doxycycline 
100mg 
Doxycycline 
100mg 
KINAPHARMA 
LIMITED. North 
Industrial Area, 
Accra (Ghana) 
Dantokpa Market, 
Cotonou. 
March 2, 2010 
Blister has a name 
Doxykin; 
Mistake in dosage 
form/strength. 
Doxycyclingélules PB 
100mg instead of BP 
100mg 
 
 
 
Annex 6: Samples collected in Togo: March 6
th 
to March16
th
, 2010. 
Official sources confirm that the pharmaceutical sector suffers from insufficiency of medicine 
professionals; one pharmacist for 300 patients according to the ministry of health. This situation 
should not be an excuse for turning a blind eye to the illicit medicine markets. Medicine sellers 
expose their goods on market stalls under inadequate storage conditions (high temperature). The 
itinerant hawkers are frequently met on streets even on the compounds of ministries. The sellers 
ignore that high temperatures may damage the potency of medicines they are carrying. 
Brand Name Active Substance/ 
Strength 
Manufacturer/ 
Distributor 
Procurement 
Site/Date 
Concerns 
Amoxicillin 
500mg 
Amoxicillin 
500mg 
Letap 
Pharmaceuticals 
Ltd. PO.BOX 
3346, Accra 
Assiganme 
Market Third 
Floor./ 
March 9, 2010 
No package leaflet; that means no 
instructions for patients. 
Cipox500® Ciprofloxacin 
500mg 
ZIM 
Laboratories Ltd. 
B-21/22 MIDC 
Kalmeshwar 
Nagpur 441501 
India 
Assiganme 
Market, Lome 
(Togo). / March 
9, 2010. 
Inadequate package leaflet 
(repetition of composition 
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Cipro® 
500mg USP 
Ciprofloxacin 
500mg 
ZMC Hamburg 
GmbH, 
Germany.  
Assiganme 
Market Third 
Floor./ 
March 9, 2010 
The package leaflet is written with 
mistakes example Dosage form: 
Ciprofloxacin. 
Cipromax® 
fort 500 
Ciprofloxacin Hcl 
500mg USP 
Greenfield 
Pharmaceutical 
(Jiang Su) China 
Assiganme 
Market./ 
 March 9, 2010. 
Information on packaging leaflet is 
not legible, leaflet too small. 
Concerns on readability. 
RGI 
Doxycycline 
100mg® 
Doxycycline 
100mg 
Richy Gold  
International Ltd 
Assiganme 
Market./ 
 March 9, 2010. 
 
 
It was mentioned on the package: 
Indication: Please refer to the leaflet 
although there was no leaflet in the 
package. “Store in a cool, dry and 
dark place” was translated 
“Entreposer dans une place fraiche 
et sèche”. This is not the correct 
translation. 
Shalcip500
®: 
 
Ciproflaxacin500g 
USP 
Shalina 
Laboratories 
PVT Ltd., Mubai 
(India). 
Assiganme 
Market/. 
March 9, 2010 
The generic name Ciprofloxacin 
does not include the strength 
(500mg). The labeling of the storage 
conditions was not adequate. 
Tetra250® Tetracycline HCl 
250mg 
Sprukfield (UK) 
SARL BP. 1218 
Lome Togo 
Assiganme 
Market./ 
March 9, 2010. 
 
 
No packaging leaflet attached. On 
the blister no instructions concerning 
side effect, dosage is not specified 
(as directed by the physician), no 
indication is mentioned. 
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9.2. Appendixes: 
 
 
 
 
 
Appendix 1:  
Itinerant Hawker in Abidjan's Streets 
 
 
  
Appendix 2:  
Illegal Drug Store in Lomé (Togo) 
 
 
 
 
 
 
 
Appendix 3: 
Medicines from a Hawker in Abidjan's (Cote d'Ivoire) 
Streets 
 
  
Appendix4:  
Medicines exposed to the sun 
(high temperatures) for sale in the market 
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Appendix 5 & Appendix 6: 
Illicit medicine marketing scenario in Ouagadougou (Burkina Faso) 
 
 
 
 
 
 
 
 
 
 
Appendix 7:  
Street Pharmacy in Cotonou (Benin) 
 
  
Appendix 8:  
Street Market for Medicines in Lomé (Togo) 
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Appendix 9: 
Street Market for Medicines  
in Lomé (Togo) 
 
 
  
Appendix 10:  
Market Stall of Medicines; Scenario in  
Sub-Saharan Africa 
 
 
 
 
 
 
 
 
 
Appendix 11: 
Illegal stocking of medicines; but the administration 
closed such a drug store just for the non-payment of 
taxes; it means they close eyes to the legality aspect of 
such transactions 
 
  
Appendix 12: 
If the administration closed such a drug store 
 just for the non-payment of taxes, it would 
 mean that they close eyes to the legality  
aspect of such transactions 
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9.3. Figures and Tables 
 
ServanTech GmbH & Co. KG, Dieselstr. 18, 61191 Rosbachv.d.Höhe  April 2010 
 
Fig 8: Raman spectrum of Metronidazole tablet (black) and pure API (red) 
 
 
Fig 9: Raman application to Doxycap( Doxycycline) : API (red) identified in the product    
spectrum (Blue).Fluorescence present, but enough Raman signal to evaluate the sample. 
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Figure 10: Implication of Prequalification: Failure rate of product analyzed 1997-2010 
Source: Mission for Essential Drugs and Supply. Available from www.meds.or.ke.Internet accessed on March 
7
th
, 2011 
 
 
 
Table 11: Results from GPHF Minilab and visual inspection 
Products/ 
procurement 
place 
Manufacturer/ 
batch number 
Visual test Coloration Disintegration Thin layer 
chromatography 
Cipromed® 
500mg 
(Togo) 
Medrel 
Pharmaceutical(In
dia) PVP / S91198 
No 
manufacturing 
site address; no 
company; no 
distributor 
references 
 
Test not done 
due to shortage 
of time 
 
The tablet 
disintegrates 
in water at 
37° within 30 
minutes 
 
The result 
indicates the 
presence of 
ciprofloxacin 
Ciproxamed® 
500mg 
(Côte d´Ivoire) 
Medrel 
Pharmaceutical 
(India) PVT 
/CPS805 
No 
manufacturing 
site address; no 
company; no 
distributor 
references 
 
Test not done 
due to allocated 
time 
The tablet 
disintegrates 
in water at 
37° within 30 
minutes 
 
The result 
indicates the 
presence of 
ciprofloxacin 
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Maloxin® 
(Sulfadoxin 
USP500mg+Pyri
methamine 
USP25mg 
(Burkina Faso) 
ShreeChem 
Research 
Laboratories 
(India) 
EM 396 
NAFDAC.04-
1611 
Blister is very 
hard to rip; the 
packaging 
leaflet contains 
no excipients 
Poor coloration 
Yellow 
Major defect; 
after 
60minutes, 
not 
disintegrate 
No remarkable 
spot under 
 UV 254 
Maloxin® 
(Sulfadoxin 
USP500mg+Pyri
methamine 
USP25mg 
(Nigeria) 
Gracure 
Pharmaceutical 
(India) 
Nr. TE 2445 
 
Blister is easy 
to rip.; the 
packaging 
leaflet contains 
information on 
excipients 
Intensive 
yellow 
compared to 
batch from 
SchreeChem 
Laboratories. 
Less orange 
compared to the 
reference drug 
Has passed 
disintegration 
within 
30minutes 
Remarkable 
spot at the same 
level for the 
reference drug 
Shalcip 500mg® Shalina 
Laboratories 
(India) Nr: 
MHDRUGS/PD 
189 
Abbreviation on 
the packaging 
leaflet: ENT / 
ORL were not 
explained. 
 
Test not done 
due to allocated 
time 
The tablet 
disintegrates 
in water at 
37° within 30 
minutes 
 
The result 
indicates the 
presence of 
ciprofloxacin 
Tetra 250mg® 
(Togo) 
Togo Sprukfield 
(UK) 
GMbH/AV09003 
 
No packaging 
leaflet 
More intense 
colour 
compared to the 
reference drug 
Test not done 
due to 
allocated time 
Test not done 
due to allocated 
time 
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Table 12: Some parameters of medicines market in survey countries (data from countries reports) 
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P
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M
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n
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D
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u
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Retail outlets 
(Shops are 
outlets not 
under 
supervision 
of 
pharmacist) 
B
en
in
 February 
2010 
9.033 $26 $47 57 235 2 5 245 shops 
B
u
rk
in
a 
F
as
o
 
January 
2010 14.784 $27 $39 49 245 
5(including 
.traditional 
medicines) 
6 155 
C
o
te
 
d
´i
v
o
ir
e February 
2010 19.262 $35 $67 54 933 
8(including
. 
inactives) 
3 
No data 
available 
G
h
an
a 
February 
2010 23.478 $33 $51 57 1798 29 
 no 
data 
1186 operated 
by 
pharmacist, 
9814 licensed 
outlet 
N
ig
er
ia
 
January 
2010 
148.09
3 
$33 $64 49 
6748 
[29] 
132 
(approx. 60 
registered 
995 
1604,and 
undetermined 
shops 
T
o
g
o
 March 
2010 6.48 $ 19 $45 55 230 2 4 
No, data 
available 
Sources: WHO. World Health Statistics 2009, and Data from countries survey   
 [29] FIP 2009 FIP Global Pharmacy Workforce Report. Available in Page 23, from Assessment of  
 medicines regulatory systems in Sub-Saharan African countries - WHO/EMP/QSM/2010.4 
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